def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
þ |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Amicus Therapeutics, Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its
filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
|
April 25,
2008
Dear Stockholder:
We are pleased to invite you to attend our 2008 Annual Meeting
of Stockholders to be held at the Princeton Marriott
Hotel & Conference Center at Forrestal, 100 College
Road, Princeton, New Jersey on Tuesday, June 10, 2008, at
10:00 a.m. Eastern Daylight Time.
Enclosed are the following:
|
|
|
|
|
Our Notice of Annual Meeting of Stockholders and Proxy Statement
for 2008;
|
|
|
|
Our Annual Report on
Form 10-K
for 2007; and
|
|
|
|
A proxy card with a return envelope to record your vote.
|
The accompanying notice of the 2008 Annual Meeting and Proxy
Statement describe the business we will conduct at the meeting
and provide information about Amicus Therapeutics, Inc. that you
should consider when you vote your shares.
Your vote is important. When you have finished reading the Proxy
Statement, please promptly vote your shares by marking, signing,
dating and returning the proxy card in the enclosed envelope or
vote via telephone or internet according to the instructions in
the Proxy Statement. If you attend the Annual Meeting, you may
vote your shares in person even though you have previously voted
by proxy if you follow the instructions in the Proxy Statement.
We encourage you to vote by proxy so that your shares will be
represented and voted at the meeting, whether or not you can
attend in person.
Sincerely,
John F. Crowley
President and Chief Executive Officer
April 25,
2008
TABLE OF CONTENTS
NOTICE OF 2008 ANNUAL MEETING OF STOCKHOLDERS
To our Stockholders:
The 2008 Annual Meeting of Stockholders of Amicus Therapeutics,
Inc. will be held at the Princeton Marriott Hotel &
Conference Center at Forrestal, 100 College Road, Princeton, New
Jersey on June 10, 2008 at 10:00 a.m. Eastern
Daylight Time. The purpose of this meeting is to vote on the
following:
|
|
|
|
1.
|
Elect three Class I directors each to serve a
three-year term expiring at the 2011 Annual Meeting or
until their respective successors have been elected.
|
|
|
2.
|
Approve the Amended and Restated 2007 Equity Incentive Plan.
|
|
|
3.
|
Ratify the appointment of Ernst & Young LLP as the
Companys independent registered public accounting firm for
the fiscal year ending December 31, 2008.
|
|
|
4.
|
Consider and act upon any other business that is properly
presented at the meeting.
|
These items of business are more fully described in the Proxy
Statement accompanying this Notice.
The record date for the 2008 Annual Meeting is April 21,
2008. Only stockholders of record at the close of business on
that date are entitled to notice of and to vote at the meeting
or any adjournment thereof.
BY ORDER OF THE BOARD OF DIRECTORS
Geoffrey P. Gilmore
Senior Vice President, General Counsel and Secretary
Cranbury, New Jersey
April 25, 2008
You are cordially invited to attend the meeting in person.
Whether or not you expect to attend the meeting, please
complete, date, sign and return the proxy card or vote by
telephone or the internet as instructed in the accompanying
materials as promptly as possible in order to ensure your
representation at the meeting. You can revoke a proxy at any
time prior to its exercise by following the instructions in the
proxy statement. Please note, however, that if your shares are
held of record by a broker, bank or other nominees and you wish
to vote at the meeting, you must provide a valid proxy issued in
your name from that record holder.
AMICUS
THERAPEUTICS, INC.
6 Cedar Brook Drive, Cranbury, New
Jersey 08512
(609) 662-2000
PROXY
STATEMENT FOR THE AMICUS THERAPEUTICS, INC.
2008 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON
JUNE 10, 2008
GENERAL
INFORMATION ABOUT THE ANNUAL MEETING
Why Did
You Send Me this Proxy Statement?
We sent you this Proxy Statement and the enclosed proxy card
because the Board of Directors of Amicus Therapeutics, Inc.
(sometimes referred to as Amicus or the
Company) is soliciting your proxy to vote at the
2008 Annual Meeting of Stockholders (the Annual
Meeting) and any adjournments of the meeting to be held at
the Princeton Marriott Hotel & Conference Center at
Forrestal, 100 College Road, Princeton, New Jersey on Tuesday,
June 10, 2008 at 10:00 a.m. Eastern Daylight
Time. This Proxy Statement along with the accompanying Notice of
Annual Meeting of Stockholders summarizes the purposes of the
meeting and the information you need to know to vote at the
Annual Meeting. You are invited to attend the Annual Meeting to
vote on the proposals described in this Proxy Statement. You do
not need to attend the Annual Meeting to vote your shares.
Instead you may simply complete, sign and return the enclosed
proxy card, or follow the instructions on the enclosed proxy
card to submit your proxy by telephone or on the internet.
We intend to mail this Proxy Statement, our 2007 Annual Report
on
Form 10-K,
the attached Notice of Annual Meeting and the enclosed proxy
card to all stockholders entitled to vote at the Annual Meeting
on or about April 25, 2008. You can also find a copy of our
2007 Annual Report on
Form 10-K
on the Internet through the Securities and Exchange Commission
(SEC) website at www.sec.gov or through the Investor
Relations section of our web site at
www.amicustherapeutics.com.
Who Can
Vote?
Only stockholders of record at the close of business on
April 21, 2008 are entitled to vote at the Annual Meeting.
On this record date, there were 22,501,463 shares of our
common stock (Common Stock) outstanding and entitled
to vote. Each share of Common Stock is entitled to one vote. The
Common Stock is our only outstanding class of voting stock.
Stockholder
of Record: Shares Registered in Your Name
If, on April 21, 2008, your shares were registered directly
in your name with our transfer agent, American Stock
Transfer & Trust Company, then you are a
stockholder of record. As a stockholder of record, you may vote
in person at the Annual Meeting or vote by proxy. Whether or not
you attend the Annual Meeting, we urge you to fill out and
return the enclosed proxy card or follow the instructions on the
proxy card to submit your vote by telephone or internet to
ensure your vote is counted.
Beneficial
Owner: Shares Registered in the Name of a Broker or
Bank
If, on April 21, 2008, your shares were held, not in your
name, but rather in an account at a brokerage firm, bank,
dealer, or other similar organization, then you are the
beneficial owner of shares held in street name and
these proxy materials are being forwarded to you by that
organization. The organization holding your account is
considered the stockholder of record for purposes of voting at
the Annual Meeting. As a beneficial owner, you have the right to
direct your broker or other agent on how to vote the shares in
your account. A number of brokers and banks enable beneficial
owners to give voting instructions via telephone or the
internet. Please refer to the voting instructions provided by
your bank or broker. You are also invited to attend the Annual
Meeting. However, since you are not the stockholder of record,
you may not vote your shares in person at the meeting unless you
provide a valid proxy from your broker, bank or other custodian.
What am I
voting on?
There are three matters scheduled for a vote:
|
|
|
|
|
Election of three Class I directors;
|
|
|
|
Approval of the Amended and Restated 2007 Equity Incentive Plan;
and,
|
|
|
|
Ratification of the selection of Ernst & Young LLP as
our independent registered public accounting firm for our fiscal
year ending December 31, 2008.
|
How Do I
Vote?
Whether you plan to attend the Annual Meeting or not, we urge
you to vote by proxy. Voting by proxy will not affect your right
to attend the Annual Meeting.
Stockholder of Record: If your shares are
registered directly in your name, you may vote:
|
|
|
|
|
By mail. Complete and mail the enclosed proxy
card in the enclosed postage prepaid envelope. Your proxy will
be voted in accordance with your instructions. If you sign the
proxy card but do not specify how you want your shares voted,
they will be voted as recommended by our Board of Directors.
|
|
|
|
In person at the meeting. If you attend the
meeting, you may deliver your completed proxy card in person or
you may vote by completing a ballot, which will be available at
the meeting.
|
|
|
|
By telephone. You may vote over the telephone
by calling toll-free 1-800-PROXIES
(1-800-776-9437)
in the United States or 1-718-921-8500 from outside the United
States and follow the recorded instructions. Please have your
proxy card available when you call. Your vote must be received
by 11:59 p.m. Eastern Daylight Time on June 9,
2008 to be counted.
|
|
|
|
Internet. You may vote over via the internet
by going to www.voteproxy.com and follow the
on-screen instructions. Please have your proxy card available
when you access the web page. Your vote must be received by
11:59 p.m. Eastern Daylight Time on June 9, 2008
to be counted.
|
Beneficial Owner: If your shares are held in
street name (held in the name of a bank, broker or
other nominee), you must provide the bank, broker or other
nominee with instructions on how to vote your shares and can do
so as follows:
|
|
|
|
|
By mail. You will receive instructions from
your broker or other nominee explaining how to vote your shares.
|
|
|
|
In person at the meeting. Contact the broker
or other nominee who holds your shares to obtain a brokers
proxy card and bring it with you to the meeting. You will not be
able to vote at the meeting unless you have a proxy card from
your broker.
|
How Many
Votes do I have?
Each share of Common Stock that you own as of April 21,
2008, entitles you to one vote on each matter to be voted on at
the Annual Meeting.
What if I
return a proxy card but do not make specific choices?
If you return a signed and dated proxy card without marking any
voting selections, your shares will be voted
For the election of all three nominees for
director, For the Amended and Restated 2007
Equity Incentive Plan, and For ratification
of the selection of Ernst & Young LLP as our
independent registered public accounting firm for our fiscal
year ending December 31, 2008. If any other matter is
properly presented at the Annual Meeting, your proxy (one of the
individuals named on your proxy card) will vote your shares
using his best judgment.
2
Will My
Shares be Voted if I Do Not Return My Proxy Card?
If your shares are registered in your name, they will not be
voted if you do not return your proxy card by mail or vote at
the meeting as described above under How Do I Vote?
If your shares are held in street name and you do not provide
voting instructions to the bank, broker or other nominee that
holds your shares as described above under How Do I
Vote?, the bank, broker or other nominee has the authority
to vote your unvoted shares on both Proposals 1 and 3 even
if it does not receive instructions from you. However, they do
not have the authority to vote on Proposal 2 because
brokers do not have discretionary voting authority on this
matter. We encourage you to provide voting instructions. This
ensures your shares will be voted at the meeting in the manner
you desire. If your broker cannot vote your shares on a
particular matter because it has not received instructions from
you and does not have discretionary voting authority on that
matter or because your broker chooses not to vote on a matter
for which it does have discretionary voting authority, this is
referred to as a broker non-vote.
May I
Revoke My Proxy?
If you give a proxy, you may revoke it at any time before the
Annual Meeting. You may revoke your proxy in any one of the
following ways:
|
|
|
|
|
signing a new proxy card and submitting it as instructed above;
|
|
|
|
notifying the Companys Secretary in writing before the
Annual Meeting that you have revoked your proxy; or
|
|
|
|
attending the meeting in person and voting in person if you are
a stockholder of record. Attending the meeting in person will
not in and of itself revoke a previously submitted proxy unless
you specifically request it.
|
What if I
Receive More Than One Proxy Card?
You may receive more than one proxy card or voting instruction
form if you hold shares of our Common Stock in more than one
account, which may be in registered form or held in street name.
Please vote in the manner described under How Do I
Vote? for each account to ensure that all of your shares
are voted.
How Does
the Board of Directors Recommend That I Vote on the
Proposals?
The Board of Directors recommends that you vote as follows:
|
|
|
|
|
FOR the election of the nominees for director;
|
|
|
|
FOR the approval of the Amended and Restated
2007 Equity Incentive Plan; and
|
|
|
|
FOR ratification of the selection of
Ernst & Young LLP as our independent registered public
accounting firm for our fiscal year ending December 31,
2008.
|
If any other matter is properly presented, the proxy card
provides that your shares will be voted by the proxy holder
listed on the proxy card in accordance with his or her best
judgment. At the time this Proxy Statement was printed, we knew
of no matters that needed to be acted on at the Annual Meeting,
other than those discussed in this Proxy Statement.
3
What Vote
is Required to Approve Each Proposal and How are Votes
Counted?
|
|
|
Proposal 1: Elect Directors
|
|
The nominees for director who receive the most votes (also known
as a plurality of the votes) will be elected.
Abstentions are not counted as voting on the matter for purposes
of electing directors. You may vote FOR all of the nominees,
WITHHOLD your vote from all of the nominees or WITHHOLD your
vote from any one or more of the nominees. Votes that are
withheld will not be included in the vote tally for the election
of directors. Brokerage firms have authority to vote
customers unvoted shares held by the firms in street name
for the election of directors. If a broker does not exercise
this authority, such broker non-votes will have no effect on the
results of this vote.
|
|
|
|
|
|
|
Proposal 2: Approve the Amended and Restated 2007 Equity
Incentive Plan
|
|
The affirmative vote of a majority of the votes cast at the
Annual Meeting is required to approve the Amended and Restated
2007 Equity Incentive Plan. Abstentions will have the effect of
a vote against this proposal. Brokerage firms do not have the
authority to vote customers unvoted shares held by the
firms in street name on this proposal. If the broker does not
receive instructions on this Proposal 2, the broker non-votes
will have the effect of vote against this Proposal 2. Our Board
of Directors has approved the Amended and Restated 2007 Equity
Incentive Plan and believes it is in the best interest of the
stockholders to approve it.
|
|
|
|
|
|
|
Proposal 3: Ratify Selection of Independent Registered Public
Accounting Firm
|
|
The affirmative vote of a majority of the votes cast at the
Annual Meeting is required to ratify the selection of
independent registered public accounting firm. Abstentions will
have the effect of a vote against this proposal. Brokerage firms
have authority to vote customers unvoted shares held by
the firms in street name on this proposal. If a broker does not
exercise this authority, such broker non-votes will have no
effect on the results of this vote. We are not required to
obtain the approval of our stockholders to select our
independent registered public accounting firm. However, our
Board of Directors believes it is advisable to give stockholders
the opportunity to ratify this selection. If our stockholders do
not ratify the selection of Ernst & Young LLP as our
independent registered public accounting firm for the fiscal
year ending December 31, 2008, the Audit Committee of our Board
of Directors will reconsider its selection.
|
How are
votes counted?
Votes will be counted by the inspector of election appointed for
the Annual Meeting, who will separately count For
and Withhold and (with respect to proposals other
than the election of directors) Against votes,
abstentions and broker non-votes. Shares represented by
abstentions and broker non-votes will be counted in determining
whether there is a quorum for the Annual Meeting. Abstentions
and broker non-votes will not be counted towards the vote total
for any proposal.
Is Voting
Confidential?
We will keep all the proxies, ballots and voting tabulations
private. We only let our Inspectors of Election, American Stock
and Transfer and our legal counsel examine these documents.
Management will not know how you voted on a specific proposal
unless it is necessary to meet legal requirements. We will,
however, forward to management any written comments you make, on
the proxy card or elsewhere.
What Are
the Costs of Soliciting these Proxies?
We will pay all of the costs of soliciting these proxies. Our
directors and employees may solicit proxies in person or by
telephone, fax or email. We will pay these employees and
directors no additional compensation for these services. We will
ask banks, brokers and other institutions, nominees and
fiduciaries to forward these proxy
4
materials to their principals and to obtain authority to execute
proxies. We will then reimburse them for their expenses.
What
Constitutes a Quorum for the Meeting?
The presence, in person or by proxy, of the holders of a
majority of the outstanding shares of our Common Stock is
necessary to constitute a quorum at the meeting. Votes of
stockholders of record who are present at the meeting in person
or by proxy, abstentions and broker non-votes are counted for
purposes of determining whether a quorum exists.
How can I
find out the results of the voting at the Annual
Meeting?
Preliminary voting results will be announced at the Annual
Meeting. Final voting results will be published in our quarterly
report on
Form 10-Q
for the second quarter of 2008.
When are
stockholder proposals due for next years Annual
Meeting?
If you wish to submit a proposal to be considered for inclusion
in next years proxy materials or nominate a director, your
proposal must be in proper form according to SEC
Regulation 14A,
Rule 14a-8
and received by the Secretary of the Company on or before
February 10, 2009. If you wish to submit a proposal to be
presented at the 2009 Annual Meeting of Stockholders but which
will not be included in the Companys proxy materials, your
proposal must be submitted in writing and in conformance with
our By-laws to Amicus Therapeutics, Inc., 6 Cedar Brook Drive,
Cranbury, NJ 08512 Attn: Secretary no earlier than
December 26, 2008 and no later than January 25, 2009.
You are advised to review our By-laws, which contain additional
requirements about advance notice of stockholder proposals and
director nominations.
Attending
the Annual Meeting
The Annual Meeting will be held at the Princeton Marriott
Hotel & Conference Center at Forrestal,
100 College Road, Princeton, New Jersey on Tuesday,
June 10, 2008 at 10:00 a.m. Eastern Daylight
Time. When you arrive at the Princeton Marriott
Hotel & Conference Center at Forrestal, signs will
direct you to the appropriate meeting rooms. You are not
required to attend the Annual Meeting in order to vote.
5
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect
to the beneficial ownership of our Common Stock as of
March 31, 2008 for (a) the executive officers named in
the Summary Compensation Table contained in this Proxy
Statement, (b) each of our directors and director nominees,
(c) all of our current directors and executive officers as
a group and (d) each stockholder known by us to own
beneficially more than 5% of our Common Stock. Beneficial
ownership is determined in accordance with the rules of the SEC
and includes voting or investment power with respect to the
securities.
We deem shares of Common Stock that may be acquired by an
individual or group within 60 days of March 31, 2008
pursuant to the exercise of options to be outstanding for the
purpose of computing the percentage ownership of such individual
or group, but are not deemed to be outstanding for the purpose
of computing the percentage ownership of any other person shown
in the table. Except as indicated in footnotes to this table, we
believe that the stockholders named in this table have sole
voting and investment power with respect to all shares of Common
Stock shown to be beneficially owned by them based on
information provided to us by these stockholders. Percentage of
ownership is based on 22,491,356 shares of Common Stock
outstanding on March 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage
|
|
|
|
|
of Shares
|
|
|
Number of Shares
|
|
Beneficially
|
Name and Address of Beneficial Owner
|
|
Beneficially Owned
|
|
Owned
|
|
5% Stockholders
|
|
|
|
|
|
|
|
|
Entities affiliated with New Enterprise Associates(1)
|
|
|
4,513,582
|
|
|
|
20.1
|
%
|
1119 St. Paul Street
Baltimore, MD 21202
|
|
|
|
|
|
|
|
|
Entities affiliated with Frazier Healthcare Ventures(2)
|
|
|
3,520,678
|
|
|
|
15.7
|
%
|
601 Union, Two Union Square, Suite 3200
Seattle, WA 98101
|
|
|
|
|
|
|
|
|
Entities affiliated with Prospect Venture Partners II, L.P.(3)
|
|
|
2,240,752
|
|
|
|
10.0
|
%
|
435 Tasso Street, Suite 200
Palo Alto, CA 94301
|
|
|
|
|
|
|
|
|
Entities affiliated with CHL Medical Partners(4)
|
|
|
2,108,554
|
|
|
|
9.4
|
%
|
1055 Washington Boulevard, 6th Floor
Stamford, CT 06901
|
|
|
|
|
|
|
|
|
Entities affiliated with Canaan Partners(5)
|
|
|
2,050,790
|
|
|
|
9.1
|
%
|
285 Riverside Avenue, Suite 250
Westport, CT 06880
|
|
|
|
|
|
|
|
|
Entities affiliated with Quaker BioVentures(6)
|
|
|
1,419,762
|
|
|
|
6.3
|
%
|
Cira Center
2929 Arch Street
Philadelphia, PA
19104-2868
|
|
|
|
|
|
|
|
|
Entities affiliates with Baker Brothers Life Sciences, L.P.
|
|
|
1,378,662
|
|
|
|
6.1
|
%
|
667 Madison Avenue,
17th Floor
New York, NY 10065
|
|
|
|
|
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage
|
|
|
|
|
of Shares
|
|
|
Number of Shares
|
|
Beneficially
|
Name and Address of Beneficial Owner
|
|
Beneficially Owned
|
|
Owned
|
|
Executive Officers and Directors
|
|
|
|
|
|
|
|
|
John F. Crowley(8)
|
|
|
546,701
|
|
|
|
2.4
|
%
|
David Palling, Ph.D.(9)
|
|
|
93,274
|
|
|
|
*
|
|
Matthew R. Patterson(10)
|
|
|
158,638
|
|
|
|
*
|
|
Gregory P. Licholai, M.D.(11)
|
|
|
80,778
|
|
|
|
*
|
|
James E. Dentzer(12)
|
|
|
69,306
|
|
|
|
*
|
|
S. Nicole Schaeffer(13)
|
|
|
44,648
|
|
|
|
*
|
|
David Lockhart, Ph.D.(14)
|
|
|
102,083
|
|
|
|
*
|
|
Bradley L. Campbell(15)
|
|
|
13,603
|
|
|
|
*
|
|
Andrew Shenker, M.D., Ph.D
|
|
|
|
|
|
|
*
|
|
John Kirk
|
|
|
|
|
|
|
*
|
|
Geoffrey P. Gilmore
|
|
|
|
|
|
|
*
|
|
Donald J. Hayden, Jr.(16)
|
|
|
59,440
|
|
|
|
*
|
|
Alexander E. Barkas, Ph.D.(3)
|
|
|
2,240,752
|
|
|
|
10.0
|
%
|
Michael G. Raab(1)
|
|
|
4,513,029
|
|
|
|
20.1
|
%
|
James N. Topper, M.D., Ph.D.(2)
|
|
|
3,520,678
|
|
|
|
15.7
|
%
|
Glenn P. Sblendorio(17)
|
|
|
14,333
|
|
|
|
*
|
|
Stephen Bloch, M.D.(18)
|
|
|
2,050,790
|
|
|
|
9.1
|
%
|
Gregory M Weinhoff, M.D.(19)
|
|
|
2,108,554
|
|
|
|
9.4
|
%
|
P. Sherrill Neff(6)
|
|
|
1,419,762
|
|
|
|
6.3
|
%
|
All directors and executive officers as a group
(19 persons)(20)
|
|
|
18,415,031
|
|
|
|
81.9
|
%
|
|
|
|
* |
|
Represents beneficial ownership of less than one percent of our
outstanding Common Stock. |
|
(1) |
|
Consists of 3,659,157 shares held of record by New
Enterprise Associates 11, Limited Partnership, 2,689 shares
held of record by NEA Ventures 2004, Limited Partnership, and
821,736 shares held of record by New Enterprise Associates
9, Limited Partnership. Voting and investment power over the
shares held by NEA Ventures 2004, Limited Partnership is
exercised by J. Daniel Moore, its general partner. Voting and
investment power over the shares held by New Enterprise
Associates 9, Limited Partnership is exercised by NEA Partners
9, Limited Partnership, its general partner. The individual
general partners of NEA Partners 9, Limited Partnership are C.
Richard Kramlich, Peter J. Barris, Charles W. Newhall, III,
Mark W. Perry and John M. Nehra. Voting and investment power
over the shares held by New Enterprise Associates 11, Limited
Partnership is exercised by NEA Partners 11, Limited
Partnership, its general partner. The general partner of NEA
Partners 11, Limited Partnership is NEA 11 GP, LLC. The
individual managers of NEA 11 GP, LLC are C. Richard Kramlich,
Peter J. Barris, Charles W. Newhall, III, Mark W. Perry,
Scott D. Sandell, Eugene A. Trainor, III, Charles M.
Linehan, Ryan D. Drant, Krishna Kittu Kolluri and M.
James Barrett. Mr. Raab is a partner of New Enterprise
Associates but does not have voting or dispositive power with
respect to the shares held by New Enterprise Associates 11,
Limited Partnership, New Enterprise Associates 9, Limited
Partnership or NEA Ventures 2004, Limited Partnership.
Mr. Raab and each of the aforementioned indirect holders of
the shares held by New Enterprise Associates 11, Limited
Partnership, New Enterprise Associates 9, Limited Partnership
and NEA Ventures 2004, Limited Partnership disclaims beneficial
ownership of such shares except to the extent of their
respective pecuniary interest therein, if any. |
|
(2) |
|
Consists of 2,586,886 shares held of record by Frazier
Healthcare IV, L.P., 13,128 shares held of record by
Frazier Affiliates IV, L.P. and 920,664 shares held of
record by Frazier Affiliates V, L.P. Dr. Topper, a
member of our Board of Directors, holds the title of General
Partner with Frazier Healthcare Ventures. In that capacity he
shares voting and investment power for the shares held by both
Frazier Healthcare IV, L.P. and Frazier |
7
|
|
|
|
|
Affiliates IV, L.P. Dr. Topper disclaims beneficial
ownership of the shares held by entities affiliated with Frazier
Healthcare Ventures, except to the extent of any pecuniary
interest therein. |
|
(3) |
|
Consists of 2,207,144 shares held of record by Prospect
Venture Partners II, L.P., and 33,608 shares held of record
by Prospect Associates II, L.P. Dr. Barkas, a member of our
Board of Directors and a Managing Member of the General Partner
of both Prospect Venture Partners II, L.P. and Prospect
Associates II, L.P., disclaims beneficial ownership of the
shares held by entities affiliated with Prospect Venture
Partners II, L.P. except, to the extent of any pecuniary
interest therein. |
|
(4) |
|
Consists of 1,975,455 shares held of record by CHL Medical
Partners II, L.P. and 133,099 shares held of record by CHL
Medical Partners II Side Fund, L.P. Voting and investment
power over the shares held by each of the partnerships
constituting CHL Medical Partners is exercised by Collinson
Howe & Lennox II, L.L.C. in its role as general
partner and investment advisor to the partnerships. The members
of Collinson Howe & Lennox II, L.L.C. are Jeffrey J.
Collinson, Myles D. Greenberg, Timothy F. Howe, Ronald W.
Lennox, and Gregory M. Weinhoff, a member of our Board of
Directors. Each of these members disclaims beneficial ownership
of these shares except to the extent of his proportionate
pecuniary interest therein. |
|
(5) |
|
Consists of 1,976,967 shares held of record by Canaan
Equity III, L.P., and 73,823 shares held of record by
Canaan Equity III Entrepreneurs, LLC. Canaan Equity
Partners III, LLC, the sole general partner of Canaan Equity
III, L.P. and sole manager of Canaan Equity III
Entrepreneurs, LLC, has sole voting and disposition power over
these shares. The Managers of Canaan Equity Partners, III,
LLC are John V. Balen, Stephen L. Green, Deepak Kamra, Gregory
Kopchinsly, Seth A. Rudnick, Guy M. Russo and Eric A. Young.
Dr. Bloch, a member of our Board of Directors, is a member
of Canaan Equity Partners III, LLC. Dr. Bloch does not have
sole or shared voting or disposition power over these shares. |
|
(6) |
|
Consists of 1,064,822 shares held of record by Quaker
BioVentures, L.P. and 354,940 shares held of record by
Garden State Life Sciences Venture Fund, L.P. Mr. Neff, a
member of our Board of Directors and a Member of the General
Partner of both Quaker BioVentures, L.P., and Garden State Life
Sciences Venture Fund, L.P. disclaims beneficial ownership of
the shares held by entities affiliated with Quaker BioVentures,
except to the extent of any pecuniary interest therein. |
|
(7) |
|
Consists of 2,611 shares held of record by Baker Bros.
Investments II, L.P., 340,666 shares held of record by
Baker Biotech Fund I, L.P., 998,436 shares held of
record by Baker Brothers Life Sciences, L.P., 31,739 shares
held of record by 14159, L.P. and 5,210 shares held of
record by Baker/Tisch Investments, L.P. |
|
(8) |
|
Consists of 351,299 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 195,402 shares held of record. Includes
78,736 shares held of record by John F. Crowley,
13,333 shares held of record by MPAJ, LLC, for which
Mr. Crowley has sole voting and dispositive power,
45,000 shares held of record by Aileen A. Crowley 2007
Grantor Retained Annuity Trust, and 58,333 shares held of
record by John F. Crowley 2007 Grantor Retained Annuity Trust.
Mr. Crowley is the sole trustee of the John F. Crowley 2007
Grantor Retained Annuity Trust and exercises voting and
investment power over its shares. Mr. Crowley disclaims
beneficial ownership of the shares held by the Aileen A. Crowley
2007 Grantor Retained Annuity Trust. |
|
(9) |
|
Consists of 43,242 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 50,032 shares held of record. |
|
(10) |
|
Consists of 82,189 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 76,449 shares held of record. |
|
(11) |
|
Consists of 73,960 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 6,818 shares held of record. Includes
6,666 shares held of record by the Gregory P. Licholai 2006
Grantor Retained Annuity Trust, for which Mr. Licholai has
sole voting and dispositive power. |
|
(12) |
|
Consists of 33,051 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008 and 36,255 shares subject to forfeiture under a
restricted stock agreement. In order to satisfy certain tax
withholding obligations, Mr. Dentzer surrenders a portion
of his vested shares on each vesting date. |
|
(13) |
|
Consists of 31,853 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 12,795 shares held of record. |
8
|
|
|
(14) |
|
Consists of 102,083 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008. |
|
(15) |
|
Consists of 13,603 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008. |
|
(16) |
|
Consists of 59,440 shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008. |
|
(17) |
|
Consists of 13,333 shares granted under a restricted stock
agreement and 1,000 shares held of record. |
|
(18) |
|
Consists of shares beneficially owned by entities affiliated
with Canaan Partners, as described in footnote (5) above.
Dr. Bloch does not have sole or shared voting or
dispositive power over shares owned by entities affiliated with
Canaan Partners. Dr. Bloch disclaims beneficial ownership
of such shares, except to the extent of his pecuniary interest
therein. |
|
(19) |
|
Consists of shares beneficially owned by entities affiliated
with CHL Medical Partners, as described in footnote
(4) above. Dr. Weinhoff, a member of our Board of
Directors and a member of the general partner of both CHL
Medical Partners II, L.P. and CHL Medical Partners II Side
Fund, L.P., disclaims beneficial ownership of the shares held by
entities affiliated with CHL Medical Partners, except to the
extent of any pecuniary interest therein. |
|
(20) |
|
Consists of 790,720 total shares issuable upon the exercise of
stock options exercisable within 60 days of March 31,
2008, and 22,491,356 total shares held of record. |
9
MANAGEMENT
The Board
of Directors
Our Restated Certificate of Incorporation and Restated By-laws
provide that our business is to be managed by or under the
direction of our Board of Directors. Our Board of Directors is
divided into three classes for purposes of election. One class
is elected at each Annual Meeting of Stockholders to serve for a
three-year term. Our Board of Directors currently consists of
nine members, divided into three classes as follows:
|
|
|
|
|
The Class I directors are Drs. Barkas and Bloch, and
Mr. Neff, and their term will expire at the 2008 Annual
Meeting of Stockholders;
|
|
|
|
The Class II directors are Drs. Topper and Weinhoff,
and Mr. Hayden, and their term will expire at the annual
meeting of stockholders to be held in 2009; and
|
|
|
|
The Class III directors are Messrs. Crowley, Raab, and
Sblendorio, and their term will expire at the annual meeting of
stockholders to be held in 2010.
|
On April 22, 2008, our Board of Directors, upon the
recommendation of the Nominating and Corporate Governance
Committee, voted to nominate Alexander E. Barkas, Stephen Bloch
and P. Sherrill Neff for re-election as Class I directors
at the 2008 Annual Meeting for a term of three years to serve
until the 2011 Annual Meeting of stockholders, and until their
respective successors have been elected and qualified.
Our Restated Certificate of Incorporation and Restated By-laws
provide that the authorized number of directors may be changed
only by resolution of the Board of Directors. Our Board of
Directors has authorized that the size of the Board be set at
nine members.
Set forth below are the names of the directors, nominees and our
other directors whose terms do not expire this year, their ages
as of April 25, 2008, their offices in the Company, if any,
their principal occupations or employment for the past five
years, the length of their tenure as directors and the names of
other public companies in which such persons hold directorships:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
|
John F. Crowley
|
|
|
41
|
|
|
President and Chief Executive Officer and Director
|
Donald J. Hayden(3)
|
|
|
52
|
|
|
Chairman and Director
|
Alexander E. Barkas, Ph.D.(3)
|
|
|
60
|
|
|
Director
|
Michael G. Raab(1)(3)
|
|
|
43
|
|
|
Director
|
Glenn P. Sblendorio(2)
|
|
|
52
|
|
|
Director
|
Stephen Bloch, M.D.(2)
|
|
|
46
|
|
|
Director
|
James N. Topper, M.D., Ph.D.(1)
|
|
|
46
|
|
|
Director
|
Gregory M. Weinhoff, M.D.(2)
|
|
|
37
|
|
|
Director
|
P. Sherrill Neff(1)
|
|
|
56
|
|
|
Director
|
|
|
|
(1) |
|
Member of Compensation Committee. |
|
(2) |
|
Member of Audit Committee. |
|
(3) |
|
Member of Nominating/Corporate Governance Committee. |
The following is a brief summary of the background of each of
our directors:
John F. Crowley has served as President and Chief
Executive Officer since January 2005, and has also served as a
Director of Amicus since August 2004, with the exception of the
period from September 2006 to March 2007 when he was not an
officer or director of Amicus while he was in active duty
service in the United States Navy (Reserve). He was President
and Chief Executive Officer of Orexigen Therapeutics, Inc. from
September 2003 to December 2004. Mr. Crowley was President
and Chief Executive Officer of Novazyme Pharmaceuticals, Inc.,
from March 2000 until that company was acquired by Genzyme
Corporation in September 2001; thereafter he served as Senior
Vice President of Genzyme Therapeutics until December 2002.
Mr. Crowley received a B.S. degree in
10
Foreign Service from Georgetown Universitys School of
Foreign Service, a J.D. from the University of Notre Dame Law
School, and an M.B.A. from Harvard Business School.
Donald J. Hayden, Jr. has served as Chairman since
March 2006 and from September 2006 until March 2007 he served as
Interim President and Chief Executive Officer. From 1991 to
2005, he held several executive positions with Bristol-Myers
Squibb Company, most recently serving as Executive Vice
President and President, Americas. Mr. Hayden holds a B.A.
from Harvard University and an M.B.A. from Indiana University.
Alexander E. Barkas, Ph.D., has served as a member
of our Board of Directors since 2004. Since 1997,
Dr. Barkas has been a co-founder and served as a managing
member of the general partner of a series of Prospect Venture
Partners funds. Dr. Barkas serves as the chairman of
the Board of Directors of two publicly-held biotechnology
companies, Geron Corporation and Tercica, Inc., and as a
director of several private biotechnology and medical device
companies. He holds a B.A. from Brandeis University and a Ph.D.
from New York University.
Michael G. Raab has served as a member of our Board of
Directors since 2004. Mr. Raab has served as a partner of
New Enterprise Associates since June 2002. From 1999 to 2002, he
was a Senior Vice President, Therapeutics and General Manager,
Renagel®
at Genzyme Corporation. Mr. Raab is a director of Novacea,
Inc. Mr. Raab holds a B.A. from DePauw University.
Glenn P. Sblendorio has served as a member of our Board
of Directors since June 2006. Mr. Sblendorio has served as
Chief Financial Officer and Executive Vice President of The
Medicines Company since March 2006. Prior to joining The
Medicines Company, Mr. Sblendorio was Executive Vice
President and Chief Financial Officer of Eyetech
Pharmaceuticals, Inc. from February 2002 until it was acquired
by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to
February 2002, Mr. Sblendorio served as Senior Vice
President of Business Development at The Medicines Company.
Mr. Sblendorio received his B.B.A. from Pace University and
his M.B.A. from Fairleigh Dickinson University.
James N. Topper, M.D., Ph.D., has served as a
member of our Board of Directors since 2004. Dr. Topper has
been a partner with Frazier Healthcare Ventures since August
2003, holding the position of General Partner since 2004. Prior
to joining Frazier Healthcare, he served as Head of the
Cardiovascular Research and Development Division of Millennium
Pharmaceuticals and ran Millennium San Francisco (formerly
COR Therapeutics) from 2002 until 2003. Prior to the merger of
COR and Millennium in 2002, Dr. Topper served as the Vice
President of Biology at COR from August 1999 to February 2002.
He holds an appointment as a Clinical Assistant Professor of
Medicine at Stanford University and as a Cardiology Consultant
to the Palo Alto Veterans Administration Hospital.
Dr. Topper currently serves on the Board of La Jolla
Pharmaceutical Company. Dr. Topper holds an M.D. and a
Ph.D. in Biophysics from Stanford University School of Medicine.
Stephen Bloch, M.D., has served as a member of our
Board of Directors since 2004. He has served as a venture
partner at Canaan Partners since June 2002. Prior to joining
Canaan, Dr. Bloch founded and served as the Chief Executive
Officer of Radiology Management Sciences, a risk manager of
diagnostic imaging services for health plans and provider
networks, from 1995 to 2002. Dr. Bloch received his M.D.
from the University of Rochester. He also received a M.A. in
history of science from Harvard University and an A.B. degree in
history from Dartmouth College.
Gregory M. Weinhoff, M.D. has served as a member of
our Board of Directors since our inception. Since 2001,
Dr. Weinhoff has served as a Member of Collinson
Howe & Lennox II, L.L.C., the general partner of CHL
Medical Partners II, L.P. Dr. Weinhoff served as our
founding Chief Executive Officer from inception until October
2002. From 2000 to 2001, Dr. Weinhoff was a Senior
Associate at Whitney & Co. Dr. Weinhoff holds an
A.B. degree from Harvard College, an M.D. degree from Harvard
Medical School and an M.B.A. degree from Harvard Business School.
P. Sherrill Neff has served as a member of our Board
of Directors since 2005. Mr. Neff is a founding partner of
Quaker BioVentures, L.P. and has been with the firm since 2002.
Prior to forming Quaker BioVentures, L.P., he was President,
Chief Operating Officer, and a director of Neose Technologies,
Inc. from 1994 to 2002. Mr. Neff has also previously served
as the Senior Vice President, Corporate Development at
U.S. Healthcare, Managing Director of Alex,
Brown & Son and a corporate attorney at Morgan,
Lewis & Bockius. Mr. Neff currently sits on the
Board of
11
Resource Capital Corporation. Mr. Neff is a graduate of
Wesleyan University and the University of Michigan Law School.
Director
Independence
Our Board of Directors has reviewed the materiality of any
relationship that each of our directors has with Amicus, either
directly or indirectly. Based on this review, the Board has
determined that the following directors are independent
directors as defined by the rules and regulations of The
Nasdaq Stock Market: Messrs. Hayden, Neff, Raab and
Sblendorio, and Drs. Barkas, Bloch, Topper and Weinhoff.
Committees
of the Board of Directors and Meetings
Our Board of Directors has an audit committee, a compensation
committee, and a nominating and governance committee, each of
which has the composition and responsibilities described below.
Audit Committee. Our Audit Committee met eight
times during 2007. The current members of our Audit Committee
are Mr. Sblendorio and Drs. Bloch and Weinhoff. Our
Board has also determined that Mr. Sblendorio is an audit
committee financial expert within the meaning of Item 7 (d)
(3) (iv) of Schedule 14A of the Securities and
Exchange Act of 1934, as amended (the Exchange Act)
and has Accounting or related financial management
expertise within the meaning of the rules and regulation
of the Nasdaq Stock Market. Our Audit Committee was established
in accordance with Section 3(a)(58) of the Exchange Act.
Our Audit Committee assists our Board of Directors in its
oversight of the integrity of our financial statements, our
independent registered public accounting firms
qualifications and independence and the performance of our
independent registered public accounting firm.
Our Audit Committees responsibilities include:
|
|
|
|
|
appointing, approving the compensation of, and assessing the
independence of our independent registered public accounting
firm;
|
|
|
|
overseeing the work of our independent registered public
accounting firm, including through the receipt and consideration
of certain reports from our independent registered public
accounting firm;
|
|
|
|
reviewing and discussing with management and the independent
registered public accounting firm our annual and quarterly
financial statements and related disclosures;
|
|
|
|
monitoring our internal control over financial reporting,
disclosure controls and procedures and code of business conduct
and ethics;
|
|
|
|
establishing policies regarding hiring employees from our
independent registered public accounting firm and procedures for
the receipt and retention of accounting related complaints and
concerns;
|
|
|
|
meeting independently with our independent registered public
accounting firm and management; and
|
|
|
|
preparing the Audit Committee report required by SEC rules.
|
All audit and non-audit services to be provided to us by our
independent registered public accounting firm must be approved
in advance by our Audit Committee.
The Nasdaq Stock Market rules require that all members of the
audit committee be independent directors, as defined by the
rules of The Nasdaq Stock Market and the SEC. Our Board of
Directors has determined that all the members of the Audit
Committee satisfy the independence requirements for service on
the Audit Committee.
A copy of the Audit Committees written charter is publicly
available on our web site at www.amicustherapeutics.com.
Compensation Committee. Our Compensation
Committee met eight times during 2007. Messrs. Neff and
Raab and Dr. Topper are the members of our Compensation
Committee. Mr. Neff is the chair of the Committee. Our
Compensation Committee assists our Board of Directors in the
discharge of its responsibilities relating to the compensation
of our executive officers. In addition to the assistance
provided by Amicus Vice President of Human Resources in
the fourth quarter of 2007, the Committee retained Watson Wyatt
Worldwide (Watson Wyatt) as
12
outside advisors to the Committee. Watson Wyatt reports directly
to the Committee and provides guidance on matters including
trends in executive and non-employee director compensation, the
development of certain executive compensation programs and other
matters as directed by the Committee. Watson Wyatt does not
provide any other services to Amicus.
Our Compensation Committees responsibilities include:
|
|
|
|
|
reviewing and approving, or making recommendations to our Board
of Directors with respect to, the compensation of our chief
executive officer and our other executive officers;
|
|
|
|
overseeing the evaluation of performance of our senior
executives;
|
|
|
|
overseeing and administering, and making recommendations to our
Board of Directors with respect to our cash and equity incentive
plans;
|
|
|
|
reviewing and approving potential executive and senior
management succession plans; and
|
|
|
|
reviewing and approving non-routine employment agreements,
severance agreements and change in control agreements.
|
We believe that the composition of our Compensation Committee
meets the requirements for independence under the rules and
regulations of the Nasdaq Stock Market.
A copy of the Compensation Committees written charter is
publicly available on our web site at
www.amicustherapeutics.com.
Further discussion of the process and procedures for considering
and determining executive compensation, including the role that
our executive officers play in determining compensation for
other executive officers, is included below in the section
entitled Compensation Discussion and Analysis.
Please also see the report of the Compensation Committee set
forth elsewhere in this Proxy Statement.
Nominating and Governance Committee. Our
Nominating and Governance Committee met once during 2007.
Messrs. Hayden, Barkas and Raab are the members of our
Nominating and Corporate Governance Committee. Mr. Hayden
chairs the Committee.
Our Nominating and Corporate Governance Committees
responsibilities include:
|
|
|
|
|
recommending to our Board of Directors the persons to be
nominated for election as directors and to each of the Board of
Directors Committees;
|
|
|
|
conducting searches for appropriate directors;
|
|
|
|
reviewing the size, composition and structure of our Board of
Directors;
|
|
|
|
developing and recommending to our Board of Directors corporate
governance principles;
|
|
|
|
overseeing a periodic self-evaluation of our Board of Directors
and any Board committees; and
|
|
|
|
overseeing compensation and benefits for directors and Board
committee members.
|
We believe that the composition of our Nominating and Corporate
Governance Committee meets the requirements for independence
under the rules and regulations of the Nasdaq Stock Market.
A copy of the Nominating and Governance Committees written
charter is publicly available on our web site at
www.amicustherapeutics.com.
Policies
Governing Director Nominations
Director Qualifications. Our Nominating and
Corporate Governance Committee is responsible for reviewing with
the directors from time to time the appropriate qualities,
skills and characteristics desired of members of the Board in
the context of the needs of the business and the composition of
the Board. This assessment includes
13
consideration of the following minimum qualifications that the
Nominating and Corporate Governance Committee believes must be
met by all directors:
|
|
|
|
|
a reputation for integrity, honesty and adherence to high
ethical standards;
|
|
|
|
the ability to exercise sound business judgment;
|
|
|
|
substantial business or professional experience and the ability
to offer meaningful advice and guidance to the Companys
management based on that experience; and
|
|
|
|
to devote the time and effort necessary to fulfill their
responsibilities to the Company.
|
The Nominating and Corporate Governance Committee also considers
numerous other qualities, skills and characteristics when
evaluating director nominees, including whether the nominee has
specific strengths that would augment existing skills and
experience of the Board, such as an understanding of and
experience in technology, accounting, governance, finance or
marketing and whether the nominee has leadership experience with
public companies or other sophisticated and complex
organizations.
Process for Identifying and Evaluating Director
Nominees. Our Nominating and Corporate Governance
Committee has established a process for identifying and
evaluating nominees for director. Although the Nominating and
Corporate Governance Committee will consider nominees
recommended by stockholders, the Committee believes that the
process it uses to identify and evaluate nominees for director
is designed to produce nominees that possess the educational,
professional, business and personal attributes that are best
suited to further the Companys mission. The Committee may
identify nominees through the use of professional search firms
that may utilize proprietary screening techniques to match
candidates to the Committees specified qualifications. The
Committee may also receive recommendations from existing
directors, executive officers, key business partners, and trade
or industry affiliations. The Committee will evaluate
nominations at regular or special meetings, and in evaluating
nominations, will seek to achieve a balance of knowledge,
experience and capability on the Board and to address the
membership criteria set forth above under Director
Qualifications. The Board itself is ultimately responsible
for recommending candidates for election to the stockholders or
for appointing individuals to fulfill a vacancy.
In 2007, we did not employ a search firm or pay fees any third
party to either search for or evaluate Board nominee candidates.
Procedures for Recommendation of Director Nominees by
Stockholders. The Nominating and Corporate
Governance Committee will consider director candidates
recommended by our stockholders. In evaluating candidates
recommended by our stockholders, the Nominating and Corporate
Governance Committee applies the same criteria set forth above
under Director Qualifications. Any stockholder
recommendations of director nominees proposed for consideration
by the Nominating and Governance Committee should include the
nominees name and qualifications for Board membership and
should be addressed in writing to the Committee, care of: Amicus
Therapeutics Inc., 6 Cedar Brook Drive, Cranbury, New Jersey
08512, Attention: Secretary. In addition, our By-laws permit
stockholders to nominate directors for consideration at an
annual stockholder meeting in accordance with certain procedures
described in this Proxy Statement under the heading
Stockholder Proposals and Nominations for Director.
Meeting Attendance. During the year ended
December 31, 2007, there were 15 meetings of our Board of
Directors, and the various committees of the Board met a total
of 17 times. No director attended fewer than 75% of the total
number of meetings of the Board and of committees of the Board
on which he or she served during 2007. The Board has adopted a
policy under which each member of the Board is strongly
encouraged to attend each Annual Meeting of our Stockholders.
Compensation Committee Interlocks and Insider
Participation. None of our executive officers
serves as a member of the Board of Directors or compensation
committee, or other committee serving an equivalent function, of
any entity that has one or more of its executive officers
serving as a member of our Board of Directors or our
Compensation Committee. None of the members of our Compensation
Committee has ever been our employee.
14
Stockholder
Communications to the Board
Any stockholders who wish to address questions regarding our
business directly with the Board of Directors, or any individual
director, should direct his or her questions in writing to the
Chairman of the Board
c/o Amicus
Therapeutics, Inc. at 6 Cedar Brook Drive, Cranbury, NJ 08512.
Communications will be distributed to the Board, or to any
individual director or directors as appropriate, depending on
the facts and circumstances outlined in the communications.
Executive
Officers
The following is a brief summary of the background of each of
our executive officers:
John F. Crowley, 41, has served as President and Chief
Executive Officer since January 2005, and has also served as a
Director of Amicus since August 2004, with the exception of the
period from September 2006 to March 2007 when he was not an
officer or director of Amicus while he was in active duty
service in the United States Navy (Reserve). He was President
and Chief Executive Officer of Orexigen Therapeutics, Inc. from
September 2003 to December 2004. Mr. Crowley was President
and Chief Executive Officer of Novazyme Pharmaceuticals, Inc.,
from March 2000 until that company was acquired by Genzyme
Corporation in September 2001; thereafter he served as Senior
Vice President of Genzyme Therapeutics until December 2002.
Mr. Crowley received a B.S. degree in Foreign Service from
Georgetown Universitys School of Foreign Service, a J.D.
from the University of Notre Dame Law School, and an M.B.A. from
Harvard Business School.
Matthew R. Patterson,36, has served as Chief Operating
Officer since September 2006. From December 2004 to September
2006 he served as Chief Business Officer. From
1998-2004,
Mr. Patterson worked at BioMarin Pharmaceuticals Inc. where
he was Vice President, Regulatory and Government Affairs from
2001 to 2003 and later Vice President, Commercial Planning from
2003-2004.
From
1993-1998,
Mr. Patterson worked at Genzyme Corporation in Regulatory
Affairs and Manufacturing. Mr. Patterson received a B.A. in
Biochemistry from Bowdoin College.
James E. Dentzer, 41, has served as Chief Financial
Officer since October 2006. From November 2003 to October 2006,
Mr. Dentzer was Corporate Controller at Biogen Idec Inc.
From 2001 until the 2003 merger of Biogen, Inc. and IDEC
Pharmaceuticals Corporation, Mr. Dentzer served as
Corporate Controller of Biogen, Inc. Prior to that, he served in
a variety of financial positions at E. I. du Pont de Nemours and
Company, most recently as Chief Financial Officer of DuPont
Flooring Systems. Mr. Dentzer received his B.A. from Boston
College and his M.B.A. from the University of Chicago.
David J. Lockhart, Ph.D., 46, has served as
Chief Scientific Officer since January 2006. Prior to joining
Amicus, Dr. Lockhart served as President, Chief Scientific
Officer and co-founder of Ambit Biosciences, a biotechnology
company specializing in small molecule kinase inhibitors, from
March 2001 to July 2005. Dr. Lockhart served as a
consultant to Ambit Biosciences from August 2000 to March 2001,
and as a visiting scholar at the Salk Institute for Biological
Studies from October 2000 to March 2001. Prior to that,
Dr. Lockhart served in various positions, including Vice
President of Genomics Research at Affymetrix, and was the
Director of Genomics at the Genomics Institute of the Novartis
Research Foundation from February 1999 to July 2000. He received
his Ph.D. from Stanford University and was a post-doctoral
fellow at the Whitehead Institute for Biomedical Research at the
Massachusetts Institute of Technology.
David Palling, Ph.D., 54, has served as
Senior Vice President, Drug Development, since August, 2002.
From September 1998 until August, 2002, Dr. Palling was
with Johnson & Johnson, most recently serving as Vice
President of Worldwide Assay Research and Development at Ortho
Clinical Diagnostics, a subsidiary of Johnson &
Johnson. Dr. Palling received B.Sc. and Ph.D. degrees in
Chemistry from the University of London, Kings College,
and conducted post-doctoral research in Biochemistry at Brandeis
University.
Gregory P. Licholai, M.D., 43, has served as
Vice President, Medical Affairs since January 2005. From
November 2002 to December 2004, Dr. Licholai was with
Domain Associates, a venture capital firm. From September 2000
to November 2002, he was director of Ventures and Business
Associates for Medtronic Neurological, a division of Medtronic,
Inc. Dr. Licholai received his B.A. from Boston College and
completed Pre-
15
Medical studies at Columbia University, his M.D. from Yale
Medical School and his M.B.A. from Harvard Business School.
S. Nicole Schaeffer, 40, has served as Vice
President, Human Resources and Leadership Development since
March 2005. From 2001 to 2004, she served as Senior Director,
Human Resources, for three portfolio companies of Flagship
Ventures, a venture capital firm, and in that capacity she
managed human resources for three life sciences companies.
Ms. Schaeffer received her B.A. from the University of
Rochester and her M.B.A. from Boston University.
Bradley L. Campbell, 32, has served as Vice President,
Business Planning since May 2007. From April 2006 until May
2007, he served as Senior Director, Business Development. From
2002 until 2006, Mr. Campbell served as Senior Product
Manager and later Business Director of CV Gene Therapy at
Genzyme Corporation. Mr. Campbell received his B.A. from
Duke University and his M.B.A. from Harvard Business School.
John R. Kirk, 51, has served as Vice President,
Regulatory Affairs since January 1, 2008. Prior to joining
Amicus, Mr. Kirk served as Executive Director, Regulatory
Affairs at Aegerion Pharmaceuticals. From 2003 to 2007,
Mr. Kirk held positions of increasing responsibility with
Esperion Therapeutics which was acquired during this time by
Pfizer. From 2000 to 2002, Mr. Kirk was Director, Worldwide
Regulatory Affairs for Pfizer Global Research and Development.
From 1988 to 2000, Mr. Kirk held various Regulatory
positions with Parke-Davis Pharmaceutical Research.
Mr. Kirk holds both his M.S. and B.S. from Wright State
University in Ohio.
Andrew Shenker M.D., Ph.D., 53, has served as Vice
President, Clinical Research since December 2007. From 2002 to
2007, Dr. Shenker was with Bristol-Myers Squibb where he
served most recently as Medical Director in the Clinical
Discovery Group. From 1995 to 2002, Dr. Shenker was
Assistant Professor of Pediatrics, Molecular Pharmacology and
Biological Chemistry at Northwestern University Medical School.
Dr. Shenker obtained his Ph.D. in pharmacology and M.D.
from the Mount Sinai School of Medicine in NYC, completed his
internship and residency in Pediatrics at the Johns Hopkins
Hospital and was a post-doctoral fellow at the National
Institutes of Health.
Geoffrey P. Gilmore, 42, has served as Senior Vice
President, General Counsel and Secretary since March 2008. Prior
to joining Amicus, from 2003 to 2008, Mr. Gilmore was in
the Law Department at Bristol-Myers Squibb Company, where most
recently he served as Vice President and Senior Counsel. From
2002 to 2003, Mr. Gilmore was a Senior Attorney at Wyeth
Pharmaceuticals. From 1997 to 2002, Mr. Gilmore held
various positions in the law department of Bristol Myers Squibb
Company. Prior to joining Bristol-Myers Squibb Company,
Mr. Gilmore was an associate with the law firms, Ballard
Spahr Andrews & Ingersoll, LLP, where he practiced in
the Business and Finance Group, and Montgomery, McCracken,
Walker & Rhoads, LLP, where he practiced in the
Corporate & Securities Group. Mr. Gilmore
received his B.A. from Franklin and Marshall College, and his
J.D. from University of Michigan Law School.
COMPENSATION
DISCUSSION AND ANALYSIS
Executive
Summary
The Compensation Committee is responsible for establishing,
implementing and overseeing our overall compensation strategy
and policies, including our executive compensation program, in a
manner that supports our business objectives.
We describe our executive compensation program below and provide
an analysis of the compensation paid and earned in 2007 by our
named executive officers our President
and Chief Executive Officer, Chief Financial Officer and three
other most highly compensated executive officers, as well as our
interim President and Chief Executive Officer, who stepped down
from serving in that capacity in 2007. In 2007, our named
executive officers were Messrs. Crowley, Hayden, Dentzer,
Patterson, Lockhart and Dr. Licholai.
16
Objectives
and Philosophy of Executive Compensation
Amicus is a clinical stage biopharmaceutical company focused on
the discovery, development and commercialization of a new class
of small molecule, orally administered drugs to treat a range of
human genetic diseases. We operate in an extremely competitive,
rapidly changing and heavily regulated industry. We believe that
the skill, talent and dedication of our executive officers and
other executives are critical factors affecting our long-term
success. Therefore, our compensation program for our executive
officers, including our named executive officers, is designed to
attract, retain and motivate the best possible executive talent.
Utilizing a pay-for-performance compensation philosophy we have
designed a program that provides the ability to differentiate
the total compensation mix of our named executive officers based
on their demonstrated performance and their potential to
contribute to our long-term success.
Our compensation philosophy is to:
|
|
|
|
|
provide our executives a competitive total compensation
opportunity relative to the organizations with which we compete
for executive talent;
|
|
|
|
attract and retain individuals of superior ability and
managerial talent who can successfully perform and succeed in
our environment;
|
|
|
|
increase the incentive to achieve key strategic and financial
performance measures by linking compensation opportunities to
the achievement of both corporate and individual performance
goals in these areas; and
|
|
|
|
deliver pay in a cost efficient manner that aligns
employees compensation with shareholders long term
interests.
|
In order to meet the objectives of our compensation philosophy
we maintain a robust goal setting and performance management
program. Corporate objectives are established at the beginning
of each year and are the basis for determining corporate
performance for the year. Key strategic corporate, financial and
operational goals that are established by our Board of Directors
include:
|
|
|
|
|
clinical trial progress;
|
|
|
|
pre-clinical drug development;
|
|
|
|
continued intellectual property development; and
|
|
|
|
implementation of appropriate financing or business development
strategies.
|
We also maintain a robust individual goal setting process that
serves as the basis for individual performance measurement at
the end of the calendar year. Our compensation program is
designed to reward the accomplishment of our corporate and
individual goals in a manner consistent with the Companys
values. Both results and how the results are attainted are
critically important. Our executives are evaluated and reviewed
on the basis of achievement of results relative to their
pre-established goals, as well as demonstrated competencies and
behavioral attributes.
Compensation
Program Elements and Pay Level Determination
Each year, the Compensation Committee reviews and determines
base salaries, annual incentive and long term incentive awards
for all executive officers. For 2007, the base salaries, annual
cash incentives and long term incentive awards determination for
all named executive officers, including our chief executive
officer were approved by our independent (non-employee)
directors.
As part of this evaluation process, the Chief Executive Officer
and the Vice President of Human Resources present to the
Compensation Committee, a detailed individual assessment of each
executive officers performance excluding his own over the
prior year, as well as the recommended compensation action for
each named executive officer. The results of the named executive
officers performance are a determination by the supervisor
and Chief Executive Officer with input from other peers, and
direct reports as appropriate. The Chief Executive
Officers performance is assessed by all independent
directors.
17
Individual goals and objectives are established at the beginning
of each year and are critical to ensuring that our compensation
program rewards each executive based on his or her success
relative to the specific goals for his or her role. All
employees participate in annual goal setting as well as mid year
and annual performance reviews.
Compensation decisions for 2007 were determined using a
methodology in place prior to our initial public offering and
reflected the Companys overall stage of development at the
time and its status as a privately held Company.
To understand external competitiveness for 2007, the
Compensation Committee reviewed market information from
companies of similar size and stage of development operating in
the biotechnology industry. For comparison purposes in 2007, we
utilized market data for companies between 50 and
149 employees. In particular, data was obtained from
Radford Biotechnology Surveys, prepared by AON Consulting, Inc.
The Compensation Committee considered all the information
presented (including external competitiveness, the performance
review, Company performance and internal equity) and applied its
collective knowledge and discretion to determine the
compensation for each named executive officer.
In 2007, Amicus Therapeutics targeted its base salary and bonus
compensation within the
45th to
75th percentile
of a broad set of companies from the Radford Life Science
Survey. As a privately held company at the commencement of 2007,
a greater emphasis was placed upon the award of stock options
within the total compensation mix. Actual compensation levels
for each named executive officer depend on factors such as
individual performance, Company performance,
skills/capabilities, overall impact/contribution, experience in
position, criticality of position and internal equity.
Mr. Crowleys compensation was above the target range.
In 2008, the Compensation Committee, with the help of its
independent executive compensation consultant, Watson Wyatt,
established a peer group to better align target compensation
with competitive data. This peer group, along with a broader set
of companies from the Radford Life Science Survey from which
executive compensation data were compiled and analyzed, served
to assist the Committee for 2008 executive compensation
decisions.
Our peer group which is listed below was selected by the
Compensation Committee, taking into account the advice of Watson
Wyatt, through a robust screening process that considered
publicly traded U.S. biopharmaceutical companies that were
similar to Amicus in size and business operating model and
operate in geographic locations that generally have similar pay
levels. The Compensation Committee intends to continue reviewing
and revising the peer group periodically to ensure that it
continues to reflect companies of similar size and business
model.
|
|
|
|
|
ACADIA Pharmaceuticals
|
|
ARIAD Pharmaceuticals
|
|
Tercica
|
Acorda Therapeutics
|
|
Pharmasset
|
|
Theravance
|
Affymax
|
|
Rigel Pharmaceuticals
|
|
Xoma Limited
|
Alnylam Pharmaceuticals
|
|
Sirtris Pharmaceuticals
|
|
|
Altus Pharmaceuticals
|
|
Synta Phrmaceuticals
|
|
|
Elements
of Compensation
Amicus executive compensation consists of a number of
elements, each of which plays an important role in our
pay-for-performance philosophy and in achieving our compensation
program objectives. For each element of compensation we target a
different position to develop an overall executive compensation
program that is competitive with 2007 market data.
Base
Salary
Base salaries are paid to our named executive officers to
provide a level of compensation that is both competitive with
the external market and is commensurate with each
employees scope of responsibilities, past performance,
experience and skills. The salary increase from 2006 to 2007 for
our named executive officers averaged 4.08% and ranged from 0%
to 6%. The range in increases accounts for the fact that
Mr. Crowley as chief executive officer did not receive a
base salary increase in 2007. In reviewing competitive market
data, the Compensation Committee determined that as a private
company, the chief executive officers base salary was at
an appropriate level. The remaining named executive officers
received merit increases based upon the 2006 performance and
market data.
18
Annual
Cash Incentive Plan
We maintain an annual cash incentive program to motivate and
reward the attainment of annual strategic, operational,
financial and individual goals. For all program participants,
annual cash incentive opportunities, which are expressed as a
percentage of base salary, are targeted within the 50th to
65th percentile of the market. These percentages of base
salary are determined by level in the organization accordance
with our plan as follows:
|
|
|
|
|
|
|
Targeted
|
|
|
|
Bonus % of
|
|
Position
|
|
Base Salary
|
|
|
Chief Executive Officer
|
|
|
50
|
%
|
Other Chief Officers
|
|
|
30
|
%
|
Vice Presidents
|
|
|
25
|
%
|
The plan provides for an individual multiplier that is
determined based upon the individual performance year end
rating. The multiplier may typically range from 0% to 120+%.
Individual multipliers for 2007 for named executive officers
ranged from 100 to 120%.
In addition, the Compensation Committee applies a corporate
multiplier based upon a determination of how the Company
performed against the previously agreed corporate goals and the
other significant corporate activities that occurred during the
year. This corporate multiplier may range from 0% to 150%. For
2007, the Compensation Committee recommended a corporate
multiplier of 100% and that multiplier was approved by the full
Board of Directors.
In reaching its recommendation on the corporate multiplier, the
Compensation Committee reviewed the goals and objectives as a
whole. The Compensation Committee determined that the
Companys successful completion of the initial public
offering and the execution of the License and Collaboration
Agreement with Shire Pharmaceuticals Ireland, Ltd., the
combination of which significantly reduced financial risk to
investors, along with substantial clinical progress in three
programs and continued overall scientific progress, more than
offset minor areas in which goals were not met completely. As
such, the Compensation Committee approved a composite 100%
corporate multiplier in recognition of the 2007 achievements.
Individual cash incentive payments equal the product of the
Company Multiplier, the Individual Multiplier, the Target Bonus
% and the Annual Base Salary. The calculation of the named
executive officers individual cash incentive payments are
summarized in the table below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company
|
|
|
Individual
|
|
|
Target
|
|
|
Base
|
|
|
|
|
|
|
Multiplier
|
|
|
Multiplier
|
|
|
Bonus
|
|
|
Salary
|
|
|
Payout
|
|
Name and Principal Position
|
|
(%)
|
|
|
(%)
|
|
|
(%)
|
|
|
($)
|
|
|
($)
|
|
|
John F. Crowley
|
|
|
100
|
|
|
|
110
|
|
|
|
50
|
|
|
$
|
400,000
|
|
|
$
|
220,000
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
100
|
|
|
|
110
|
|
|
|
50
|
|
|
|
34,615
|
|
|
|
19,000
|
|
Chairman and Interim President
and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James E. Dentzer
|
|
|
100
|
|
|
|
110
|
|
|
|
30
|
|
|
|
282,800
|
|
|
|
93,324
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
100
|
|
|
|
105
|
|
|
|
30
|
|
|
|
313,500
|
|
|
|
98,753
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
100
|
|
|
|
120
|
|
|
|
30
|
|
|
|
296,800
|
|
|
|
106,848
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory Licholai, M.D.
|
|
|
100
|
|
|
|
110
|
|
|
|
25
|
|
|
|
233,660
|
|
|
|
64,257
|
|
Vice President, Medical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employees who are hired after April 1 of the calendar year are
eligible for a prorated bonus based upon date of hire. Employees
hired after October 1 of any calendar year are not eligible to
receive an annual cash incentive award for that year.
19
Long-term
Incentive Program
We believe that long-term performance will be achieved through
an ownership culture that rewards our executives for maximizing
shareholder value over time and that aligns the interests of our
employees and management with those of stockholders. Our 2007
Equity Incentive Plan, or the 2007 Plan, and our 2002 Equity
Incentive Plan, or the 2002 Plan, authorize or authorized us to
grant stock options or restricted stock. We have historically
elected to use stock options as the primary long-term equity
incentive vehicle. We grant an initial stock option award to new
employees and performance-based awards as part of our overall
compensation program as well as option grants to reflect
promotions, as necessary. For the named executives officers
(with the exception of Mr. Hayden), our stock option awards
vest over a four year period with 25% vesting one year after the
vesting commencement date and the remainder vesting ratably each
month thereafter in equal installments over a
3-year
period subject to continued employment of association with us,
and expire ten years after the date of grant. Mr. Hayden
was granted stock options during his tenure as interim chief
executive officer with a vesting period that correlated with his
term as interim chief executive officer.
We expect to continue to use stock options as a long-term
incentive vehicle because we believe that:
|
|
|
|
|
Stock options and the vesting period of stock options attract
and retain executives.
|
|
|
|
Stock options are inherently performance based. Because all the
value received by the recipient of a stock option is based on
the growth of the stock price, stock options enhance the
executives incentive to increase our stock price and
maximize stockholder value.
|
|
|
|
Stock options help to provide a balance to the overall executive
compensation program as base salary and our annual performance
bonus program focus on short-term compensation, while stock
options reward executives for increases in shareholder value
over the longer term.
|
As the Company evolves as an organization, we will continue to
explore and evaluate the use of alternative long-term incentives
vehicles in combination with stock options.
Initial
Stock Option Awards
Executives who join us are awarded initial stock option grants.
These grants have an exercise price equal to the closing price
of our Common Stock on the date of grant, or the first date of
employment, whichever date is later. In 2007, the number of
shares of the initial stock option award was determined based on
the executives position with us and analysis of the
competitive practices of the companies similar in size to us
represented in the compensation data that we review. Our goal is
to create a total compensation package for new employees that is
competitive with other biotechnology companies and that will
enable us to attract high quality people. All stock options
awards to our named executive officers and employees are
approved by the Compensation Committee.
Annual
Stock Option
Our practice is to make annual stock option awards as part of
our overall performance management program to those employees
who earn a certain threshold of performance rating or above. The
Compensation Committee believes that providing additional option
grants beyond the initial grant provides management with a
strong link to long term corporate performance and the creation
of shareholder value.
In 2007, certain named executive officers were award stock
options in the amounts indicated in the section entitled
Grants of Plan-Based Awards. This includes stock
options granted company-wide in April 2007, including all named
executive officers. All of the stock option awards were subject
to our standard four year vesting schedule. The Compensation
Committee relied in part on the survey performed by Radford
prior to our initial public offering as a reference point to
bring our executive compensation packages more in line with
those prevailing in the market for companies similar in size and
scope as ours prior to our initial public offering.
Restricted
Stock
Our 2002 Plan and our 2007 Plan authorize us to grant restricted
stock. To date, we granted under our 2002 Plan
13,333 shares of restricted stock to Mr. Sblendorio,
our Audit Committee chairman, and 40,000 shares of
20
restricted stock to Mr. Dentzer. While we have no current
plans to grant restricted stock under our 2007 Plan, we may
choose to do so in order to implement the long-term incentive
goals of the Compensation Committee.
Other
Compensation
Consistent with our compensation philosophy, we intend to
continue to maintain our current benefits for our named
executive officers, including medical, dental, vision and life
insurance coverage. All employees receive Company paid term life
insurance equal to two times annual base salary, up to a maximum
benefit of $1,000,000.
In 2007, the Company did not provide a Company-match for our
401(k) Plan. Effective January 1, 2008, the Compensation
Committee approved the implementation of a Company match for our
401(k) Plan. Executives as all participants are subject to
Federal guidelines and plan maximums. We will match $1 for each
$1 a participant defers into the plan up to 4%, and will then
match $1 for each $2 a participant defers into the plan up to 2%
for a total maximum match of 5%.
Our Company is engaged in a highly competitive industry and
developing medicines for unique and complicated genetic
disorders. As Chief Executive Officer, Mr. Crowley has
significant responsibility for leading our Company and managing
its progress toward achieving our corporate goals.
Mr. Crowleys compensation reflects this
responsibility and takes into account his unique circumstances.
As part of his overall compensation, Mr. Crowley receives
significant payments and benefits from the Company related to
the healthcare and other associated costs incurred by his
family. Specifically, the Company provides Mr. Crowley with
two additional compensation components: (1) certain
payments pursuant to his employment agreement, and
(2) Company-paid premiums for a supplemental health
insurance plan. We describe these benefits below.
Employment Agreement Payments: As
outlined in Mr. Crowleys employment agreement, in
2007 we reimbursed Mr. Crowley the maximum annual amount of
$220,000 for medical expenses not covered by any of the
Companys medical insurance plans and made corresponding
gross-up
payments on behalf of Mr. Crowley to the appropriate
federal and state taxing authorities in the amount of $183,078,
resulting in an aggregate of $403,078 for the year. These
payments were made on a continuous basis during the course of
2007 and we decided to structure the reimbursements into
quarterly payments for 2008. Effective January 1, 2008, we
modified the agreement to (i) make quarterly payments to
Mr. Crowley to cover out-of-pocket healthcare associated
expenses incurred by Mr. Crowley and his family, and
(ii) make corresponding
gross-up
payments on behalf of Mr. Crowley on a quarterly basis to
the appropriate federal and state taxing authorities. We expect
the annual aggregate cost of these collective payments to be
approximately $403,000 for 2008.
Additional Health Insurance: In
addition to the basic health insurance plan provided to all
employees, we maintain an additional medical insurance plan in
which the named executive officers and other executives may
participate. As mentioned above, the Company initiated this
insurance plan primarily to address significant medical costs
incurred by the family of Mr. Crowley. At present, in
addition to Mr. Crowley, Mr. Patterson and
Dr. Licholai participate and receive benefits under the
plan. These executives are entitled to the reimbursement of
medical expenses, subject to certain limitations. We continually
re-evaluate the levels of benefits currently provided to our
executives.
In aggregate for 2007, the Company provided Mr. Crowley
with other compensation of $863,206, which included
reimbursements of $403,078 under his employment agreement and
$460,128 for health insurance premiums for
Mr. Crowleys family. Due to the current trends in
health care and health insurance costs and
Mr. Crowleys unique needs, the Company expects the
costs of the benefits provided to Mr. Crowley to rise
significantly in 2008. As part of its responsibilities, the
Compensation Committee intends to monitor these costs and
continuously review and assess the total mix and structure of
Mr. Crowleys compensation to ensure that it
appropriately reflects the value Mr. Crowley brings to the
Company.
Termination
Based Change of Control Compensation
Upon termination of employment under certain circumstances, our
named executive officers are entitled to receive varying types
of compensation. Elements of this compensation may include
payments based upon a number
21
of months of base salary, bonus amounts, acceleration of vesting
of equity, and health and other similar benefits. We believe
that our termination-based compensation and acceleration of
vesting of equity arrangements are in line with severance
packages offered to named executive officers of other similar
companies, including our package for our chief executive
officer, based upon the market information we have reviewed. We
also have granted severance and acceleration of vesting of
equity benefits to our named executive officers in the event of
a change of control if the executive is terminated within a
certain period of time following the change of control. We
believe this double trigger requirement maximizes
shareholder value because it prevents an unintended windfall to
management in the event of a friendly or non-hostile change of
control. Under this structure, unvested equity awards would
continue to incentivize our executives to remain with the
company after a change of control, and more appropriate than a
single trigger acceleration mechanism contingent only upon a
change of control. The specifics of each named executive
officers arrangements are described in further detail
below.
Compensation
for Mr. Hayden
For the period of time from September 2006 to March 2007 in
which Mr. Hayden was acting as interim Chief Executive
Officer, Mr. Haydens base salary and bonus was
determined based upon Mr. Crowleys compensation as
Chief Executive Officer. These amounts were prorated for the
amount of time commitment to the Company which was approximately
two and one half days per week. Mr. Hayden was the
Companys interim Chief Executive Officer during
Mr. Crowleys active duty service in the United States
Navy (Reserve).
Executive
Compensation
Summary
Compensation Table
The following table provides information regarding the
compensation that we paid during years 2007 and 2006 to each
person serving as our chief executive officer and our chief
financial officer and each of our other three most highly
compensated executive officers during years 2007 and 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
All Other
|
|
|
|
|
|
|
Fiscal
|
|
|
Salary
|
|
|
Bonus(1)
|
|
|
Awards
|
|
|
Awards(2)
|
|
|
Compensation
|
|
|
Total
|
|
Name and Principal Position
|
|
Year
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
John F. Crowley
|
|
|
2007
|
|
|
$
|
400,000
|
|
|
$
|
220,000
|
|
|
$
|
|
|
|
$
|
1,329,719
|
|
|
$
|
863,206
|
(3)
|
|
$
|
2,812,925
|
|
President and Chief
Executive Officer
|
|
|
2006
|
|
|
|
400,000
|
|
|
|
210,667
|
|
|
|
|
|
|
|
876,041
|
|
|
|
659,963
|
(4)
|
|
|
2,146,671
|
|
Donald J. Hayden, Jr.(5)
|
|
|
2007
|
|
|
|
119,615
|
(6)
|
|
|
19,000
|
|
|
|
|
|
|
|
269,874
|
|
|
|
|
|
|
|
408,489
|
|
Chairman and Interim
President and Chief
Executive Officer
|
|
|
2006
|
|
|
|
145,705
|
(7)
|
|
|
30,000
|
|
|
|
|
|
|
|
195,463
|
|
|
|
|
|
|
|
371,168
|
|
James E. Dentzer
|
|
|
2007
|
|
|
|
282,692
|
|
|
|
93,324
|
|
|
|
91,500
|
|
|
|
172,917
|
|
|
|
|
|
|
|
640,433
|
|
Chief Financial Officer
|
|
|
2006
|
|
|
|
70,000
|
(8)
|
|
|
84,000
|
|
|
|
22,875
|
|
|
|
13,822
|
|
|
|
299,461
|
(9)
|
|
|
490,158
|
|
Matthew R. Patterson
|
|
|
2007
|
|
|
|
312,981
|
|
|
|
98,753
|
|
|
|
|
|
|
|
259,132
|
|
|
|
2,115
|
(10)
|
|
|
672,981
|
|
Chief Operating Officer
|
|
|
2006
|
|
|
|
280,673
|
|
|
|
65,267
|
|
|
|
|
|
|
|
114,993
|
|
|
|
|
|
|
|
460,933
|
|
David Lockhart, Ph.D.
|
|
|
2007
|
|
|
|
296,154
|
|
|
|
106,848
|
|
|
|
|
|
|
|
540,051
|
|
|
|
59,281
|
(11)
|
|
|
1,002,334
|
|
Chief Scientific Officer
|
|
|
2006
|
|
|
|
280,000
|
|
|
|
66,547
|
|
|
|
|
|
|
|
316,375
|
|
|
|
94,926
|
(12)
|
|
|
757,848
|
|
Gregory Licholai, M.D.
|
|
|
2007
|
|
|
|
233,660
|
|
|
|
64,257
|
|
|
|
|
|
|
|
133,770
|
|
|
|
3,525
|
(10)
|
|
|
434,868
|
|
Vice President, Medical Affairs
|
|
|
2006
|
|
|
|
224,675
|
|
|
|
34,151
|
|
|
|
|
|
|
|
102,892
|
|
|
|
|
|
|
|
361,718
|
|
Joseph Warusz(13)
|
|
|
2006
|
|
|
|
48,094
|
|
|
|
|
|
|
|
|
|
|
|
161,368
|
|
|
|
124,887
|
|
|
|
334,349
|
|
Vice President, Finance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John M. McAdam(14)
|
|
|
2006
|
|
|
|
110,000
|
|
|
|
40,450
|
|
|
|
|
|
|
|
19,824
|
|
|
|
|
|
|
|
170,274
|
|
Principal Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The 2007 amount represents bonuses earned in 2007 and paid in
2008 while the 2006 amount represents bonuses earned in 2006 and
paid in 2007. |
|
(2) |
|
The value of each of the option awards was computed in
accordance with FAS 123(R) excluding the consideration of
forfeitures. The value of options is earned by the named officer
over a four year period. The |
22
|
|
|
|
|
amount presented represents the value of current and prior year
options that were earned during 2006 and 2007, respectively. |
|
(3) |
|
Includes $220,000 of payments made in connection with
reimbursements under Mr. Crowleys employment
agreement, $183,078 for corresponding reimbursement of taxes and
$460,128 for health insurance premiums for
Mr. Crowleys family. |
|
(4) |
|
Includes $214,440 of payments made in connection with
reimbursements under Mr. Crowleys employment
agreement, $188,903 for corresponding reimbursement of taxes and
$256,620 for health insurance premiums for
Mr. Crowleys family. |
|
(5) |
|
Mr. Hayden served as interim president and chief executive
officer from September 11, 2006 until March 5, 2007. |
|
(6) |
|
This amount includes all compensation paid to Mr. Hayden in
2007 and consists of $34,615 for his service as interim
president and chief executive officer from January 1, 2007
until March 5, 2007 and $85,000 for his service as chairman
of the Board of Directors. |
|
(7) |
|
This amount includes all compensation paid to Mr. Hayden in
2006 and consists of $61,538 for his service as interim
president and chief executive officer from September 11,
2006 until December 31, 2006, $25,000 for consulting
services provided from February 28, 2006 to June 27,
2006 and $59,167 for his service as chairman of the Board of
Directors. |
|
(8) |
|
Mr. Dentzer began serving as our chief financial officer in
October 2006. |
|
(9) |
|
Consists of $199,461 of relocation expenses and a $100,000
signing bonus. |
|
(10) |
|
Represents payments of health insurance premiums. |
|
(11) |
|
Represents $39,690 of relocation expenses $333 for commuting
expenses and $19,258 for reimbursement of taxes. |
|
(12) |
|
Includes $20,000 of signing bonus, $31,579 of relocation
expenses, $25,550 for commuting expenses and $17,797 for
reimbursement of taxes. |
|
(13) |
|
Mr. Waruszs employment with us ended in March 2006.
Other compensation consists of severance and salary continuance
payments made to him during 2006 in connection with his
departure. |
|
(14) |
|
Mr. McAdam has served as our Controller since March 2006.
He also served as our Interim Principal Accounting and Principal
Financial Officer from March 2006 to September 2006. |
23
Grants of
Plan-Based Awards
The following table presents information concerning grants of
plan-based awards to each of the named executive officers during
2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
|
|
|
|
|
|
Option
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
Grant
|
|
|
|
|
Number of
|
|
Exercise
|
|
Date Fair
|
|
|
|
|
Securities
|
|
Price of
|
|
Value of
|
|
|
|
|
Underlying
|
|
Option
|
|
Option
|
|
|
|
|
Options(2)
|
|
Awards
|
|
Awards(1)
|
Name and Principal Position
|
|
Grant Date
|
|
(#)
|
|
($/Sh)
|
|
($)
|
|
John F. Crowley
|
|
|
4/25/2007
|
|
|
|
200,000
|
|
|
$
|
13.425
|
|
|
$
|
1,924,800
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
4/25/2007
|
|
|
|
26,667
|
|
|
|
13.425
|
|
|
|
256,643
|
|
Chairman and Interim President and
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James E. Dentzer
|
|
|
4/25/2007
|
|
|
|
73,334
|
|
|
|
13.425
|
|
|
|
705,766
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
4/25/2007
|
|
|
|
80,000
|
|
|
|
13.425
|
|
|
|
769,920
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
4/25/2007
|
|
|
|
100,000
|
|
|
|
13.425
|
|
|
|
962,400
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory Licholai, M.D.
|
|
|
4/25/2007
|
|
|
|
13,334
|
|
|
|
13.425
|
|
|
|
128,326
|
|
Vice President, Medical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The value of restricted stock and option awards granted to our
named executive officers in 2007 was computed in accordance with
FAS 123(R) without consideration of forfeitures. |
|
(2) |
|
The option has a term of ten years and vests in accordance with
the following schedule: 25% of the total number of shares vest
on the first anniversary of the Grant Date and 1/48th of the
total number of shares vest on the first day of each calendar
month following the grant date. |
While our 2007 Equity Incentive Plan authorizes us to grant
restricted stock, we did not grant restricted stock during 2007,
nor do we currently have plans to grant restricted stock.
24
Outstanding
Equity Awards at Year-End
The following table presents the outstanding equity awards held
by each of the named executive officers as of December 31,
2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
|
Number of
|
|
Number of
|
|
|
|
|
|
Number of
|
|
Market Value of
|
|
|
Securities
|
|
Securities
|
|
|
|
|
|
Shares or
|
|
Shares or
|
|
|
Underlying
|
|
Underlying
|
|
|
|
|
|
Units of
|
|
Units of
|
|
|
Unexercised
|
|
Unexercised
|
|
Option
|
|
|
|
Stock
|
|
Stock
|
|
|
Options
|
|
Options
|
|
Exercise
|
|
Option
|
|
That Have
|
|
That Have
|
|
|
(#)
|
|
(#)
|
|
Price
|
|
Expiration
|
|
Not Vested
|
|
Not Vested
|
Name and Principal Position
|
|
Exercisable
|
|
Unexercisable
|
|
($)
|
|
Date
|
|
(#)
|
|
($)
|
|
John F. Crowley
|
|
|
28,710
|
|
|
|
81,219
|
(1)
|
|
$
|
0.638
|
|
|
|
1/6/2015
|
|
|
|
|
|
|
$
|
|
|
President and Chief Executive
|
|
|
12,824
|
|
|
|
3,666
|
(1)
|
|
|
0.638
|
|
|
|
8/17/2014
|
|
|
|
|
|
|
|
|
|
Officer
|
|
|
54,166
|
|
|
|
45,834
|
(1)
|
|
|
5.325
|
|
|
|
10/20/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
128,333
|
|
|
|
151,667
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
30,555
|
|
|
|
36,112
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
Interim President and Chief
|
|
|
13,334
|
|
|
|
|
(2)
|
|
|
8.175
|
|
|
|
9/13/2016
|
|
|
|
|
|
|
|
|
|
Executive Officer
|
|
|
|
|
|
|
26,667
|
(1)
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
James E. Dentzer
|
|
|
9,722
|
|
|
|
23,612
|
(1)
|
|
|
8.175
|
|
|
|
10/2/2016
|
|
|
|
28,334
|
(3)
|
|
|
304,591
|
|
Chief Financial Officer
|
|
|
|
|
|
|
73,334
|
(1)
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
8,045
|
|
|
|
24,136
|
(1)
|
|
|
0.638
|
|
|
|
12/15/2014
|
|
|
|
|
|
|
|
|
|
Chief Operating Officer
|
|
|
19,861
|
|
|
|
16,806
|
(1)
|
|
|
5.325
|
|
|
|
10/20/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
15,277
|
|
|
|
18,056
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
(1)
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
45,833
|
|
|
|
54,167
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
Chief Scientific Officer
|
|
|
15,278
|
|
|
|
18,056
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
(1)
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
Gregory Licholai, M.D.
|
|
|
33,519
|
|
|
|
20,118
|
(1)
|
|
|
0.638
|
|
|
|
1/3/2015
|
|
|
|
|
|
|
|
|
|
Vice President,
|
|
|
14,436
|
|
|
|
12,231
|
(1)
|
|
|
5.325
|
|
|
|
10/20/2015
|
|
|
|
|
|
|
|
|
|
Medical Affairs
|
|
|
9,160
|
|
|
|
10,840
|
(1)
|
|
|
5.325
|
|
|
|
2/28/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,334
|
(1)
|
|
|
13.425
|
|
|
|
4/25/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
25% of the total number of shares subject to the option vest at
the end of the first year, the remainder vest 1/36th per month
thereafter. |
|
(2) |
|
100% vested on March 5, 2007 due to the termination of his
service as our Interim President and Chief Executive Officer. |
|
(3) |
|
25% of the total number of shares vests on the first anniversary
of the grant date and 1/48th of the total number of shares vest
on the first day of each calendar month following the grant date. |
25
Option
Exercises and Stock Vested at Year End
The following table presents certain information concerning the
exercise of options by each of the named executive officers
during the year ended December 31, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
|
Number of
|
|
|
|
Number of
|
|
|
|
|
Shares
|
|
Value
|
|
Shares
|
|
Value
|
|
|
Acquired on
|
|
Realized
|
|
Acquired on
|
|
Realized
|
|
|
Exercise
|
|
on Exercise
|
|
Vesting
|
|
on Vesting
|
Name and Principal Position
|
|
(#)
|
|
($)
|
|
(#)
|
|
($)
|
|
John F. Crowley
|
|
|
109,907
|
|
|
$
|
1,373,218
|
|
|
|
|
|
|
$
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chairman and Interim President and
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James E. Dentzer(1)
|
|
|
|
|
|
|
|
|
|
|
11,666
|
|
|
|
197,456
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
32,366
|
|
|
|
351,883
|
|
|
|
|
|
|
|
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
In order to comply with the minimum statutory federal and
Medicare withholding rates, Mr. Dentzer surrendered a
portion of his vested shares to Amicus Therapeutics, Inc. Total
shares surrendered were 3,085 shares with a value of
$52,217. |
Pension
Benefits
None of our named executive officers participates in or has
account balances in qualified or non-qualified defined benefit
plans sponsored by us.
Nonqualified
Deferred Compensation
None of our named executive officers participate in or have
account balances in non-qualified defined contribution plans or
other deferred compensation plans maintained by us. The
Compensation Committee, which is comprised solely of independent
directors, may elect to provide our officers and other employees
with non-qualified defined contribution or deferred compensation
benefits if the Compensation Committee determines that doing so
is in our best interests.
Severance
Benefits and Change of Control Arrangements
We have agreed to provide severance benefits and change of
control arrangements to our current executives, as described
below.
John F. Crowley. We employ Mr. Crowley as
our President and Chief Executive Officer pursuant to an
employment agreement. The agreement will continue for successive
one-year terms until either Mr. Crowley or we provide
written notice of termination to the other in accordance with
the terms of the agreement. Upon the termination of his
employment by us other than for cause, or if we decide not to
extend Mr. Crowleys agreement at the end of any term,
or termination of his employment by him for good reason,
Mr. Crowley has the right to receive (i) a severance
payment in an amount equal to 18 times his monthly base salary
then in effect, payable in accordance with our regular payroll
practices, (ii) an additional payment equal to 150% of the
target bonus for the year in which the termination occurs, and
(iii) continuation of benefits for a comparable period as a
result of any such termination. Further, the vesting of all
options then held by Mr. Crowley shall accelerate by one
year. Mr. Crowley is not entitled to severance payments if
we terminate him for cause or if he resigns without good reason.
Mr. Crowley is bound by non-disclosure, inventions and
non-competition covenants that prohibit him from competing with
us during the term of his employment and for one year after
termination of employment.
26
If Mr. Crowley resigns for good reason, we or our successor
terminate him without cause, or we decide not to extend his
employment agreement at the end of any term, in each case within
3 months prior to, or 12 months following a change of
control, then Mr. Crowley has the right to receive a
severance payment in an amount equal to 24 times his monthly
base salary then in effect, payable in accordance with our
regular payroll schedule, as well as an additional payment equal
to 200% of the target bonus for the year in which the
termination occurs. In addition, Mr. Crowley is entitled to
the continuation of benefits for a comparable period as a result
of any such termination. Further, the vesting of all options
then held by him shall accelerate in full, and all repurchase
rights that we may have as to any of his stock will
automatically lapse. We believe this double trigger
requirement maximizes shareholder value because it prevents an
unintended windfall to management in the event of a friendly or
non-hostile change of control. We believe that the severance
package for our chief executive officer is in line with
severance packages offered to chief executive officers of
comparable companies as represented by compensation data we have
reviewed.
Other Named Executive Officers. We have
entered into severance agreements with the following named
executive officers: Matthew R. Patterson, James E. Dentzer,
David Lockhart and Gregory P. Licholai, M.D. If a named
executive officer is terminated without cause, then the
executive has the right to receive:
|
|
|
|
|
six months of base salary following that termination;
|
|
|
|
an amount equal to any bonus paid to such executive in the
previous year; and
|
|
|
|
vesting on options or restricted stock awards then held by them
will automatically accelerate by six months.
|
In addition, if any of our named executive officers is
terminated other than for cause within six months following
certain corporate changes or, if following those changes, the
executive resigns for good reason, then the executive has the
right to receive:
|
|
|
|
|
a lump-sum severance payment in an amount equal to 12 times the
monthly base salary in effect as of the date of the corporate
change;
|
|
|
|
payment of a bonus equal to the bonus earned in the preceding
year; and
|
|
|
|
any outstanding unvested stock options or other equity based
compensation held by the executive will fully vest (double
trigger requirement).
|
Each named executive officer is bound by non-disclosure,
inventions transfer, non-solicitation and non-competition
covenants that prohibit the executive from competing with us
during the term of his or her employment and for 12 months
after termination of employment. We believe that the severance
packages for our named executive officers are consistent with
severance packages offered to named executive officers of
comparable companies as represented by compensation data we have
reviewed.
27
Potential
Payments Upon Termination Without Cause
The following table sets forth quantitative estimates of the
benefits that would have accrued to each of our named executive
officers if his employment had been terminated without cause on
December 31, 2007. Amounts below reflect potential payments
pursuant to the employment agreements for such named executive
officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of
|
|
|
Salary
|
|
|
|
Benefit
|
|
Accelerated
|
|
|
Continuation
|
|
Bonus
|
|
Continuation
|
|
Option Vesting
|
Name and Principal Position
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
John F. Crowley
|
|
$
|
600,000
|
|
|
$
|
300,000
|
|
|
$
|
2,313,537
|
(1)
|
|
$
|
1,328,865
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chairman and Interim President and
Chief Executive Officer(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James E. Dentzer
|
|
|
141,300
|
|
|
|
84,000
|
|
|
|
|
|
|
|
10,730
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
156,750
|
|
|
|
65,267
|
|
|
|
|
|
|
|
169,500
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
148,400
|
|
|
|
66,547
|
|
|
|
|
|
|
|
90,418
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory Licholai, M.D.
|
|
|
116,830
|
|
|
|
34,151
|
|
|
|
|
|
|
|
133,314
|
|
Vice President, Medical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Benefits to be continued consist of estimated healthcare costs
and health insurance premiums for Mr. Crowleys family. |
|
(2) |
|
Mr. Hayden served as interim president and chief executive
officer from September 11, 2006 until March 5, 2007. |
Potential
Payments Upon Termination Due to Change in Control
The following table sets forth quantitative estimates of the
benefits that would have accrued to each of our named executive
officers if his employment had been terminated due to
constructive termination upon a change in control on
December 31, 2007, assuming that such termination occurred
within the period beginning on the first day of the calendar
month immediately preceding the calendar month in which the
effective date of a change in control occured and ended on the
last day of the twelfth calendar month following the calendar
month in which the effective date of a change in control occurs.
Amounts below reflect potential payments pursuant to the amended
employment agreements for such named executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of
|
|
|
Salary
|
|
|
|
Benefit
|
|
Accelerated
|
|
|
Continuation
|
|
Bonus
|
|
Continuation
|
|
Equity Vesting
|
Name and Principal Position
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
John F. Crowley
|
|
$
|
800,000
|
|
|
$
|
400,000
|
|
|
$
|
3,084,716
|
(1)
|
|
$
|
1,929,800
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interim President and
Chief Executive Officer(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James E. Dentzer
|
|
|
282,600
|
|
|
|
84,000
|
|
|
|
|
|
|
|
60,801
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew R. Patterson
|
|
|
313,500
|
|
|
|
65,267
|
|
|
|
|
|
|
|
433,190
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lockhart, Ph.D.
|
|
|
296,800
|
|
|
|
66,547
|
|
|
|
|
|
|
|
391,810
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory Licholai, M.D.
|
|
|
233,660
|
|
|
|
34,151
|
|
|
|
|
|
|
|
328,593
|
|
Vice President, Medical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
(1) |
|
Benefits to be continued consist of healthcare costs and health
insurance premiums for Mr. Crowleys family. |
|
(2) |
|
Mr. Hayden served as interim president and chief executive
officer from September 11, 2006 until March 5, 2007. |
Confidential
Information and Inventions Agreement
Each of our named executive officers has also entered into a
standard form agreement with respect to confidential information
and inventions. Among other things, this agreement obligates
each named executive officer to refrain from disclosing any of
our proprietary information received during the course of
employment and to assign to us any inventions conceived or
developed during the course of employment.
Director
Compensation
In June 2006, our Board of Directors adopted a compensation
program for our non-employee directors, or the Director
Compensation Policy. Pursuant to the Director Compensation
Policy, each member of our Board of Directors who is not our
employee receives the following cash compensation for Board
services, as applicable:
|
|
|
|
|
$45,000 per year for service as chairman;
|
|
|
|
$20,000 per year for service as a Board member;
|
|
|
|
$30,000 per year for service as chairperson of the Audit
Committee;
|
|
|
|
$30,000 for service as a financial expert;
|
|
|
|
$20,000 per year each for service as chairperson of the
Compensation Committee or the Nominating/Corporate Governance
Committee; and
|
|
|
|
$10,000 per year for service as a member of the Audit Committee
and $5,000 per year for service as a member of the Compensation
Committee or the Nominating/Corporate Governance Committee.
|
The 2007 Director Option Plan provides that each director
shall automatically receive an annual grant of options to
purchase 10,000 shares on the date of our Annual Meeting of
Stockholders and the grants will vest in full at the next Annual
Meeting of Stockholders. The exercise price of each option
granted to a non-employee director will be equal to 100% of the
fair market value on the date of grant of the shares covered by
the option. Options will have a maximum term of 10 years
measured from the grant date, subject to termination in the
event of the optionees cessation of Board service. All of
our directors are eligible to participate in our 2007 Equity
Incentive Plan.
Summary
Director Compensation Table
The following table provides information regarding the
compensation that we paid to each of our directors during the
year ended December 31, 2007, other than those directors
included in the Summary Compensation Table above.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Incentive
|
|
|
|
|
|
|
|
|
|
Fees
|
|
|
Stock
|
|
|
Option
|
|
|
Plan
|
|
|
All Other
|
|
|
|
Total
|
|
|
Earned(1)
|
|
|
Awards(2)
|
|
|
Awards
|
|
|
Compensation
|
|
|
Compensation
|
|
Name
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
Glenn P. Sblendorio(4)
|
|
$
|
116,333
|
|
|
$
|
80,000
|
|
|
$
|
36,333
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Alexander E. Barkas, Ph.D.(5)
|
|
|
14,583
|
|
|
|
14,583
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael G. Raab(3)(5)
|
|
|
17,500
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James N. Topper, M.D., Ph.D(3)
|
|
|
14,583
|
|
|
|
14,583
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stephen Bloch, M.D.(4)
|
|
|
17,500
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gregory M. Weinhoff, M.D.(4)
|
|
|
17,500
|
|
|
|
17,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P. Sherrill Neff(3)
|
|
|
23,333
|
|
|
|
23,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald J. Hayden, Jr.(5)(6)
|
|
|
85,000
|
|
|
|
85,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29
|
|
|
(1) |
|
Represents fees paid pursuant to Director Compensation Policy. |
|
(2) |
|
The restricted stock award vests in 36 equal monthly
installments. |
|
(3) |
|
Member of Compensation Committee. |
|
(4) |
|
Member of Audit Committee. |
|
(5) |
|
Member of Nominating/Corporate Governance Committee. |
|
(6) |
|
Chairman of the Board of Directors. Mr. Hayden also served
as interim president and chief executive officer from
September 11, 2006 until March 5, 2007 during
Mr. Crowleys active duty service in the United States
Navy (Reserve). The amounts above include only his fees as
Chairman and member of the Board of Directors. His compensation
related to his tenure as interim president and chief executive
officer are included in the Summary Compensation Table contained
in this Proxy Statement. |
In 2007, Mr. Sblendorio and Mr.Hayden received a full
years worth of fees while all other members of the Board
of Directors received only a portion of their annual fees. In
November 2006, all the directors other than Mr. Sblendorio
and Mr. Hayden, who represented holders of our preferred
stock, declined receiving compensation under our Director
Compensation Policy. Upon completion of our initial public
offering in May 2007, those directors elected to resume their
compensation.
Employment
Agreements
John F. Crowley. We employ Mr. Crowley as
our president and chief executive officer. Under this agreement,
Mr. Crowley is entitled to an annual base salary of
$400,000. Adjustments to his base salary are in the discretion
of our Board of Directors and we have agreed not to reduce his
base salary below $400,000. The agreement provides that
Mr. Crowley is eligible to receive a cash bonus of up to
50% of his base salary if performance criteria are met for the
year in which the bonus is to be paid. The agreement also
provides that Mr. Crowleys compensation and benefits,
including health benefits for him and his family, continue in
full during the term of any active duty service, and
Mr. Crowley received full compensation and benefits during
his active duty service from September 2006 to March 2007. The
agreement further provides that Mr. Crowley is eligible to
participate in any executive bonus plans established by the
Board from time to time. The agreement will continue for
successive one-year terms until either Mr. Crowley or we
provide written notice of termination to the other in accordance
with the terms of the agreement.
We have agreed to secure and maintain an executive medical
reimbursement contract with a named insurance company covering
Mr. Crowley, his spouse and his dependents. Beginning in
January 2008, we have agreed to (i) make quarterly payments
to Mr. Crowley to cover out-of-pocket healthcare associated
expenses incurred by Mr. Crowley and his family, and
(ii) make corresponding
gross-up
payments on behalf of Mr. Crowley on a quarterly basis to
the appropriate federal and state taxing authorities. We expect
the annual aggregate cost of these collective payments to be
approximately $403,000 for 2008. The agreement also provides for
severance benefits and change of control arrangements as
previously described in detail.
Other Named Executive Officers. We have
entered into employment agreements with the following named
executive officers: James E. Dentzer, Matthew R. Patterson and
David Lockhart, Ph.D. These agreements set forth the named
executive officers position, duties, base salary,
benefits, and severance arrangements as described previously in
the sections above. Our executive employment agreements with
Dr. Lockhart and Messrs. Patterson and Dentzer provide
for an initial term of two years, and will continue thereafter
for successive two-year periods until we provide the executive
with written notice of the end of the agreement in accordance
with its terms. There is no employment agreement in place for
Dr. Licholai and he is employed at will.
30
COMPENSATION
COMMITTEE REPORT
The Compensation Committee is comprised entirely of independent
directors. The Compensation Committee of our Board of Directors
has reviewed and discussed the Compensation Discussion and
Analysis required by Item 402(b) of
Regulation S-K,
which appears in this Proxy Statement, with our management.
Based on this review and discussion, the Compensation Committee
has recommended to the Board of Directors that the Compensation
Discussion and Analysis be included in this Proxy Statement and
our 2007 Annual Report on
Form 10-K.
Members of the Amicus Therapeutics, Inc.
Compensation Committee:
P. Sherrill Neff, Chairman
Michael G. Raab
James N. Topper, M.D., Ph.D.
SECTION 16(a)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as
amended, requires our directors, executive officers and persons
who own more than 10% of a registered class of our equity
securities to file reports of holdings and transactions in our
Common Stock with the SEC. Based on our records and other
information, we believe that, in 2007, none of our directors,
executive officers or 10% stockholders failed to file a required
report on time, other than the following: (1) In October,
November and December of 2007, shares granted to
Mr. Dentzer, our Chief Financial Officer, pursuant to a
restricted share grant vested, with certain shares surrendered
in order to satisfy certain tax withholding obligations. As a
result of clerical and administrative errors, the shares
surrendered were inadvertently omitted from the October 2007
Form 4 and the surrender of shares in November and December
2007 were not reported timely. A Form 4 reporting these
transactions was filed in January 2008. (2) NEA Partners
11, Limited Partnership, NEA Partners 9 and related persons
filed a Form 3 required in connection with the
Companys initial public offering in 2007 one day late.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
Since January 1, 2007, we have engaged in the following
transactions with our directors, executive officers and holders
of more than 5% of our voting securities on an as converted to
Common Stock basis, and affiliates of our directors, executive
officers and holders of more than 5% of our voting securities.
The following related party transactions are in addition to the
compensation agreements and other arrangements we have made
which are described as required in Management. We
believe that all of these transactions were on terms as
favorable as could have been obtained from unrelated third
parties.
On August 24, 2006, our Board of Directors adopted a formal
policy such that all transactions between us and our officers,
directors, principal stockholders and their affiliates must be
approved by a majority of the members of the Board of Directors,
including a majority of the independent and disinterested
members of the Board of Directors, and that such transactions
must be on terms no less favorable to us than those that could
be obtained from unaffiliated third parties. We do not intend at
this time to adopt specific standards for the approval of these
transactions, but instead intend to have our Board of Directors
review all such transactions on a case by case basis. Prior to
August 24, 2006, although there was no formal policy,
approval of the Board of Directors was obtained for all related
party transactions.
Private
Placement of Securities
In March 2007, we issued an aggregate of 1,976,527 shares
of our Series D redeemable convertible preferred stock at a
price of approximately $12.16935 per share for total cash
proceeds to us of approximately $24.1 million before
transaction expenses.
31
The following table sets forth the number of shares of
Series D redeemable convertible preferred stock sold to our
5% stockholders and directors and their affiliates that
converted automatically on a one-for-one basis into shares of
our Common Stock upon the closing of our initial public offering
in June 2007.
|
|
|
|
|
|
|
Number of
|
|
|
|
Shares of
|
|
|
|
Series D Redeemable
|
|
|
|
Convertible
|
|
Name
|
|
Preferred Stock
|
|
|
Entities affiliated with Prospect Venture Partners
|
|
|
111,188
|
|
Entities affiliated with New Enterprise Associates
|
|
|
1,232,603
|
|
Entities affiliated with Frazier Healthcare Ventures
|
|
|
287,607
|
|
Entities affiliated with CHL Medical Partners
|
|
|
102,717
|
|
Entities affiliated with Quaker BioVentures
|
|
|
180,782
|
|
All other less than 5% stockholders
|
|
|
61,630
|
|
|
|
|
|
|
Total
|
|
|
1,976,527
|
|
|
|
|
|
|
Certain
Relationships
Registration
Rights
Pursuant to a third amended and restated investor rights
agreement among holders of our redeemable convertible preferred
stock and us, we granted registration rights to all such
holders, to Mount Sinai School of Medicine of New York
University and to the holder of a warrant to purchase
5,333 shares of our Common Stock. Entities affiliated with
Prospect Venture Partners II, L.P., New Enterprise Associates,
Frazier Healthcare Ventures, Canaan Equity, Quaker BioVentures
and CHL Medical Partners, each a holder of 5% or more of our
voting securities, and their affiliates are parties to this
investor rights agreement.
Director
Compensation
Please see Management Director
Compensation for a discussion of options granted and other
compensation to our non-employee directors.
Executive
Compensation and Employment Agreements
Please see Management Executive
Compensation and Management Stock
Options for additional information on compensation of our
executive officers. Information regarding employment agreements
with our executive officers is set forth under
Management Employment Agreements.
CODE OF
CONDUCT AND ETHICS
We have adopted a code of conduct and ethics that applies to all
of our employees, including our principal executive officer and
principal financial and accounting officer, and our directors.
The text of the code of conduct and ethics is posted on our web
site at www.amicustherapeutics.com and will be made
available to stockholders without charge, upon request, in
writing to the Corporate Secretary,
c/o Amicus
Therapeutics, Inc. at 6 Cedar Brook Drive, Cranbury, NJ 08512.
Disclosure regarding any amendments to, or waivers from,
provisions of the code of conduct and ethics that apply to our
directors, principal executive and financial and accounting
officers will be included in a Current Report on
Form 8-K
within four business days following the date of the amendment or
waiver, unless web site posting of such amendments or waivers is
then permitted by the rules of The Nasdaq Stock Market LLC.
PROPOSAL NO. 1
ELECTION OF DIRECTORS
The Board of Directors has voted to nominate Alexander E.
Barkas, Stephen Bloch and P. Sherrill Neff for election at the
2008 Annual Meeting for a term of three years to serve until the
2011 Annual Meeting of
32
stockholders, and until their respective successors are elected
and qualified. The Class II directors, James N. Topper,
Gregory M. Weinhoff, and Donald J. Hayden, Jr., and the
Class III directors, John F. Crowley, Michael G. Raab, and
Glenn P. Sblendorio, will serve until the Annual Meetings of
Stockholders to be held in 2009 and 2010, respectively, and
until their respective successors have been elected and
qualified.
Unless authority to vote for any of these nominees is withheld,
the shares represented by the enclosed proxy will be voted
FOR the election as directors of Alexander E. Barkas,
Stephen Bloch and P. Sherrill Neff. In the event that any
nominee becomes unable or unwilling to serve, the shares
represented by the enclosed proxy will be voted for the election
of such other person as the Board of Directors may recommend in
his or her place. We have no reason to believe that any nominee
will be unable or unwilling to serve as a director.
A plurality of the shares voted at the Annual Meeting is
required to elect each nominee as a director.
The Board of Directors recommends the vote FOR
the election of each of Alexander E. Barkas, Stephen Bloch and
P. Sherrill Neff as a director, and proxies solicited by the
Board will be voted in favor thereof unless a stockholder has
indicated otherwise on the proxy.
PROPOSAL NO. 2
APPROVAL OF THE AMENDED AND
RESTATED 2007 EQUITY INCENTIVE PLAN
We are asking our stockholders to approve our Amended and
Restated 2007 Equity Incentive Plan (the 2007 Plan).
Equity compensation has historically been a key element of our
compensation program. The ability to grant stock options and
restricted stock has enabled us to attract and retain highly
talented employees. Additionally, equity awards have also
allowed us to link incentive rewards to Company performance, to
encourage employee ownership in our stock and to align the
interest of employees with those of our shareholders. Equity
based compensation, and specifically stock options, are a common
form of compensation in our industry. Without stock options, we
would be at a disadvantage against our competitors for
recruiting and retaining key talent. We would also be unable to
offer competitive total compensation packages necessary to
attract, retain and motivate individuals critical to our future
success. The 2007 Plan was prepared under the supervision of the
Compensation Committee of the Board and in consultation with
Watson Wyatt, the Compensation Committees independent
advisor. As part of its review of various compensation issues
for the Company, Watson Wyatt provided information to the
Compensation Committee comparing the size and terms of the
Companys existing 2007 Equity Incentive Plan to our peer
group and other comparable companies. As a result of this review
and after consultation with the Companys management on the
Companys current and projected hiring and retention needs,
it was determined that the Company would need additional equity
available for grant under the existing plan in the near future.
In addition, several other amendments to the existing plan were
considered in order to align the plan with certain best
practices among our peer group and the interests of
stockholders. These amendments are discussed in more detail
below. Based on this analysis, the Compensation Committee
recommended approval of the 2007 Plan to the Board. In addition
to the recommendation of the Compensation Committee, the Board
has also independently considered the 2007 Plan and believes
that the 2007 Plan is in the best interests of the Company and
its stockholders. The Board believes the 2007 Plan will serve a
critical role in attracting and retaining officers, employees
and consultants and in motivating these individuals to strive to
meet our goals. Therefore, the Board urges you to vote to
approve the 2007 Plan.
The 2007 Plan includes amendments that provide for (i) an
increase in the maximum number of shares of our Common Stock
that may be issued under our current 2007 Equity Incentive Plan
by an additional 2,000,000 shares, (ii) a limitation
on the number of shares that may be granted as restricted stock
awards or other similar type awards to 300,000 shares,
(iii) the elimination of the automatic annual increases for
the number of shares available under the 2007 Plan,
(iv) the elimination of the provision which allowed the
return of shares used by the Companys executives as
payment for stock option exercises to the pool of available
shares that may be used for awards under the 2007 Plan and
(v) a provision limiting the term of all option awards to
ten years.
As of December 31, 2007, approximately 805,901 shares
remained available for the future grant of awards under our
current 2007 Equity Incentive Plan. After the approval of the
2007 Plan, 2,054,193 shares would then be available for
issuance under the 2007 Plan, representing approximately 9% of
our total outstanding shares as of
33
March 31, 2008. Our Board of Directors approved the
substance of the amendments in the 2007 Plan on February 5,
2008 and our Board of Directors formally approved the 2007 Plan
on April 22, 2008, subject to stockholder approval. A copy
of the 2007 Equity Incentive Plan, as proposed to be amended and
restated by this proposal is attached as Appendix A to this
Proxy Statement.
The 2007 Plan is a performance-based plan that provides awards
to selected executive officers and key employees if
pre-established performance goals are met. The 2007 Plan is
intended to meet the requirements for performance-based
compensation under Section 162(m) of the Internal Revenue
Code (the Code) so that awards paid under the 2007
Plan may qualify for a federal income tax deduction. We are
required to periodically resubmit the 2007 Plan for stockholder
approval so that it can continue to qualify as performance-based
compensation.
Our Board of Directors, upon recommendation of the Compensation
Committee, has unanimously adopted, subject to stockholder
approval, the 2007 Plan, which includes amendments that provide
for an increase of the maximum number of shares of Common Stock
issuable under the current 2007 Equity Incentive Plan by
2,000,000 shares to a total of 2,966,667 shares, the
elimination of the automatic annual increases in the number of
shares available, the limitation on the number of shares that
may be used for restricted stock or other similar types of
awards, the elimination of the use of the shares provided to the
Company in connection with an executives exercise of stock
options as shares available for the grant of future awards and
the limitation on the term of options to ten years. The
Compensation Committee made these recommendations after
reviewing the number of shares available for issuance under the
current 2007 Equity Incentive Plan. The adoption of the 2007
Plan would ensure that we will continue to have available a
reasonable number of shares for our 2007 Plan and for our equity
incentive programs and that the 2007 Plan is in compliance with
Section 162(m) of the Code. The Board of Directors believes
that in order to successfully attract and retain the best
possible candidates for positions of responsibility, we must
continue to offer a competitive equity incentive program.
We are asking you to approve the proposed 2007 Plan so that we
will have a sufficient number of shares available for the
issuance of stock option and other equity awards and so that the
2007 Plan will be in compliance with Section 162(m) of the
Code. Our Board of Directors believes that the ability of the
Company to grant stock options is important in enabling us to
offer competitive compensation packages and to make the most
effective use of the shares our stockholders authorize for
incentive purposes. Therefore, the Board of Directors urges you
to vote to approve the proposed 2007 Plan.
Summary
of the Plan
The 2007 Plan provides for the grant of incentive stock options,
within the meaning of Section 422 of the Internal Revenue
Code, to employees, and non-qualified stock options and
restricted and other stock awards to our employees, directors,
and consultants.
The aggregate number of shares of our Common Stock that are
issuable upon stock options granted under the 2007 equity
incentive plan is 2,966,667 shares. The aggregate number of
shares of Common Stock that may be granted in any calendar year
to any one person pursuant to the 2007 Plan may not exceed 50%
of the aggregate number shares of our Common Stock that may be
issued pursuant to the 2007 Plan.
The 2007 Plan will be administered by the Compensation Committee
of our Board of Directors. Subject to the provisions of the 2007
Plan, the Compensation Committee has been granted the discretion
to determine when awards are made, which directors, employees or
consultants receive awards, whether an award will be in the form
of an incentive stock option, a nonqualified stock option,
restricted stock units or stock (with or without restrictions),
the number of shares subject to each award, and all other
relevant terms of the award, including vesting and acceleration
of vesting, if any. The Compensation Committee also has been
granted broad discretion to construe and interpret the 2007 Plan
and adopt rules and regulations thereunder. Options granted
under the 2007 Plan are expected to vest over a four-year period
from the date of grant in the case of employees, and over a
two-year period from the date of grant for consultants.
Our Board of Directors may amend, modify, or terminate our 2007
Plan at any time, subject to applicable rules and law and the
rights of holders of outstanding awards. Our 2007 Plan will
automatically terminate in April 2017 unless our Board of
Directors terminates it prior to that time.
34
The Board of Directors recommends the vote FOR
the approval of the Amended and Restated 2007 Equity Incentive
Plan.
PROPOSAL NO. 3
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has appointed Ernst & Young LLP,
independent registered public accounting firm, to audit our
financial statements for the fiscal year ending
December 31, 2008. The Board proposes that the stockholders
ratify this appointment. Ernst & Young LLP audited our
financial statements for the fiscal year ended December 31,
2007. We expect that representatives of Ernst & Young
will be present at the meeting, will be able to make a statement
if they so desire, and will be available to respond to
appropriate questions.
The following table presents fees for professional audit
services rendered by Ernst & Young LLP for the audit
of our annual financial statements for the years ended
December 31, 2007, and December 31, 2006, and fees
billed for other services rendered by Ernst & Young
LLP during those periods. All of such fees were approved by the
Audit Committee.
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
($ in thousands)
|
|
|
Audit Fees
|
|
$
|
339,847
|
|
|
$
|
546,838
|
|
Tax Fees
|
|
|
|
|
|
|
11,770
|
|
All Other Fees
|
|
|
5
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
339,852
|
|
|
$
|
558,610
|
|
|
|
|
|
|
|
|
|
|
Fees for audit services included fees associated with the annual
audit and the reviews of the quarterly reports on
Form 10-Q.
For 2006, the audit fees also included costs of $400,000
associated with the preparation and review of our Registration
Statements on
Form S-1
relating to our initial public offering that was planned for
2006 but completed in June 2007. Tax Fees included tax
compliance, tax advice and tax planning and All Other Fees
included subscription fees paid for access to the
Ernst & Young LLP on-line Accounting &
Auditing Research Tool.
Policy on
Audit Committee Pre-Approval of Audit and Permissible Non-audit
Services of Independent Registered Public Accounting
Firm
Consistent with SEC policies regarding auditor independence, the
Audit Committee has responsibility for appointing, setting
compensation and overseeing the work of the independent
registered public accounting firm. In recognition of this
responsibility, the Audit Committee has established a policy to
pre-approve all audit and permissible non-audit services
provided by the independent registered public accounting firm.
Prior to engagement of the independent registered public
accounting firm for the next years audit, management will
submit an aggregate estimate of services expected to be rendered
during that year for each of four categories of services to the
Audit Committee for approval.
|
|
|
|
1.
|
Audit services include audit work performed in the
preparation of financial statements, as well as work that only
the independent registered public accounting firm can reasonably
be expected to provide, including comfort letters, statutory
audits, and attest services and consultation regarding financial
accounting
and/or
reporting standards.
|
|
|
2.
|
Audit-Related services are for assurance and related
services that are traditionally performed by the independent
registered public accounting firm, including due diligence
related to mergers and acquisitions, employee benefit plan
audits, and special procedures required to meet certain
regulatory requirements.
|
|
|
3.
|
Tax services include all services performed by the
independent registered public accounting firms tax
personnel except those services specifically related to the
audit of the financial statements, and includes fees in the
areas of tax compliance, tax planning, and tax advice.
|
|
|
4.
|
Other Fees are those associated with services not
captured in the other categories.
|
35
Prior to engagement, the Audit Committee pre-approves these
services by category of service. The fees are budgeted and the
Audit Committee requires the independent registered public
accounting firm and management to report actual fees versus the
budget periodically throughout the year by category of service.
During the year, circumstances may arise when it may become
necessary to engage the independent registered public accounting
firm for additional services not contemplated in the original
pre-approval. In those instances, the Audit Committee requires
specific pre-approval before engaging the independent registered
public accounting firm.
The Audit Committee may delegate pre-approval authority to one
or more of its members. The member to whom such authority is
delegated must report, for informational purposes only, any
pre-approval decisions to the Audit Committee at its next
scheduled meeting.
In the event the stockholders do not ratify the appointment of
Ernst & Young LLP as our independent registered public
accounting firm, the Audit Committee will reconsider its
appointment.
The affirmative vote of a majority of the shares voted
affirmatively or negatively on the matter at the Annual Meeting
is required to ratify the appointment of the independent
registered public accounting firm.
The Board of Directors recommends the vote FOR to
ratify the appointment of Ernst & Young LLP as our
independent registered public accounting firm, and proxies
solicited by the Board will be voted in favor of such
ratification unless a stockholder indicates otherwise on the
proxy.
REPORT OF
AUDIT COMMITTEE
The Audit Committee of the Board of Directors, which currently
consists entirely of directors who meet the independence and
experience requirements of the rules and regulations of Nasdaq
Stock Market and Securities Exchange Act of 1934, as amended,
has furnished the following report.
The Audit Committee assists the Board in overseeing and
monitoring the integrity of our financial reporting process,
compliance with legal and regulatory requirements and the
quality of internal and external audit processes. This Committee
reviews and reassesses our charter annually and recommends any
changes to the Board for approval. The Audit Committee is
responsible for overseeing our financial reporting process on
behalf of the Board, and for the appointment, compensation,
retention, and oversight of the work of Ernst & Young
LLP. In fulfilling its responsibilities for the financial
statements for fiscal year 2007, the Audit Committee took the
following actions:
|
|
|
|
|
Reviewed and discussed the audited financial statements for the
fiscal year ended 2007 with management and Ernst &
Young LLP, our independent registered public accounting firm;
|
|
|
|
Discussed with Ernst & Young LLP the matters required
to be discussed by Statement on Auditing Standards No. 61,
as amended, as adopted by the Public Company Accounting
Oversight Board in Rule 3200T, relating to the conduct of
the audit; and
|
|
|
|
Received written disclosures and the letter from
Ernst & Young LLP regarding its independence as
required by Independence Standards Board Standard No. 1, as
adopted by the Public Company Accounting Oversight Board in
Rule 3600T. The Audit Committee further discussed with
Ernst & Young LLP the Audit Committees
independence. The Audit Committee also considered the status of
pending litigation, taxation matters and other areas of
oversight relating to the financial reporting and audit process
that the committee determined appropriate.
|
Based on the Audit Committees review of the audited
financial statements and discussions with management and
Ernst & Young LLP, the Audit Committee recommended to
the Board that the audited financial statements be included in
our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007 for filing with
the SEC.
Members of the Amicus Therapeutics, Inc.
Audit Committee
Glenn P. Sblendorio
Stephen Bloch, M.D.
Gregory M. Weinhoff, M.D.
36
OTHER
MATTERS
The Board of Directors knows of no other business which will be
presented to the 2008 Annual Meeting. If any other business is
properly brought before the 2008 Annual Meeting, proxies in the
enclosed form will be voted in accordance with the judgment of
the persons voting the proxies.
STOCKHOLDER
PROPOSALS AND NOMINATIONS FOR DIRECTOR
To be considered for inclusion in the Proxy Statement relating
to our Annual Meeting of Stockholders to be held in 2009,
stockholder proposals must be received no later than
120 days prior to the date that is one year from this
years mailing date. To be considered for presentation at
the Annual Meeting, although not included in the Proxy
Statement, proposals must be received no later than not less
than forty-five (45) or more than seventy-five
(75) days prior to the first anniversary of the date on
which we first mailed our proxy materials for the preceding
years Annual Meeting; provided, however, that in the event
that the date of the Annual Meeting is more than thirty
(30) days before or more than thirty (30) days after
the anniversary date of the preceding years Annual
Meeting, notice by the stockholder to be timely must be so
delivered not earlier than the close of business on the
ninetieth (90) day prior to such Annual Meeting and not
later than the close of business on the later of the sixtieth
(60th) day prior to such Annual Meeting or the tenth (10th) day
following the day on which we make a public announcement of the
date of such meeting.
Proposals received after that date will not be voted on at the
Annual Meeting. If a proposal is received before that date, the
proxies that management solicits for the meeting may still
exercise discretionary voting authority on the proposal under
circumstances consistent with the proxy rules of the SEC. All
stockholder proposals should be marked for the attention of the
Office of the General Counsel, Amicus Therapeutics, Inc., 6
Cedar Brook Drive, Cranbury, NJ 08512.
Our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007 (other than
exhibits thereto) filed with the SEC, which provides additional
information about us, is available on the Internet at
www.amicustherapeutics.com and is available in
paper form to beneficial owners of our Common Stock without
charge upon written request to Secretary, Amicus Therapeutics,
Inc., 6 Cedar Brook Drive, Cranbury, NJ 08512.
37
Appendix A
AMENDED
AND RESTATED
AMICUS THERAPEUTICS, INC.
2007 EQUITY INCENTIVE PLAN
This Plan is intended to encourage ownership of Common Stock by
employees, consultants and directors of the Company and its
Affiliates and to provide additional incentive for them to
promote the success of the Companys business through the
grant of Awards of shares of the Companys Common Stock.
The Plan is intended to be an incentive stock option plan within
the meaning of Section 422 of the Code but not all Awards
granted hereunder are required to be Incentive Options.
As used in the Plan the following terms shall have the
respective meanings set out below, unless the context clearly
requires otherwise:
2.1 Accelerate, Accelerated,
and Acceleration, when used with respect to
an Option, means that as of the time of reference such Option
will become exercisable with respect to some or all of the
shares of Common Stock for which it was not then otherwise
exercisable by its terms, and, when used with respect to
Restricted Stock or Restricted Stock Units, as the case may be,
means that the Risk of Forfeiture otherwise applicable to such
Restricted Stock or Restricted Stock Units, as the case may be,
shall expire with respect to some or all of the shares of
Restricted Stock or some or all of the Restricted Stock Units,
as the case may be, then still otherwise subject to the Risk of
Forfeiture.
2.2 Acquiring Person means, with respect
to any Transaction or any acquisition described in
clause (ii) of the definition of Change of Control, the
surviving or acquiring person or entity in connection with such
Transaction or acquisition, as the case may be, provided that if
such surviving or acquiring person or entity is controlled,
directly or indirectly, by any other person or entity (an
Ultimate Parent Entity) that is not itself
controlled by any entity or person that is not a natural person,
the term Acquiring Person shall mean such Ultimate
Parent Entity.
2.3 Affiliate means, with respect to any
person or entity, any other person or entity controlling,
controlled by or under common control with the first person or
entity.
2.4 Applicable Voting Control Percentage
means (i) at any time prior to the initial public offering
of the Company, a percentage greater than fifty percent (50%)
and (ii) at any time from and after the initial public
offering of the Company, twenty percent (20%).
2.5 Award means any grant or sale
pursuant to the Plan of Options, Restricted Stock, Restricted
Stock Units or Stock Grants.
2.6 Award Agreement means an agreement
between the Company and the recipient of an Award, setting forth
the terms and conditions of the Award.
2.7 Beneficial Ownership has the meaning
ascribed to such term in
Rule 13d-3,
or any successor rule thereto, promulgated by the Securities and
Exchange Commission pursuant to the Exchange Act.
2.8 Board means the Companys board
of directors.
2.9 Change of Control means (i) the
closing of any Sale of the Company Transaction or (ii) the
direct or indirect acquisition, in a single transaction or a
series of related transactions, by any person or Group (other
than the Company or a Controlled Affiliate of the Company) of
Beneficial Ownership of previously outstanding shares of capital
stock of the Company if (A) immediately after such
acquisition, such person or Group, together with their
respective Affiliates, shall own or hold shares of capital stock
of the Company possessing at least the Applicable Voting Control
Percentage of the total voting power of the outstanding
A-1
capital stock of the Company and (B) immediately prior to
such acquisition, such person or Group, together with their
respective Affiliates, did not own or hold shares of capital
stock of the Company possessing at least the Applicable Voting
Control Percentage of the total voting power of the outstanding
capital stock of the Company. Notwithstanding anything expressed
or implied in the foregoing provisions of this definition to the
contrary, any direct or indirect acquisition referred to in
clause (ii) above in this definition shall not be treated
as a Change of Control if, at any time prior to or after such
direct or indirect acquisition, a majority of the members of the
board of directors of the Company as constituted immediately
prior to such direct or indirect acquisition consent in writing
to exclude such direct or indirect acquisition from the scope of
this definition.
2.10 Code means the Internal Revenue
Code of 1986, as amended from time to time, or any successor
statute thereto, and any regulations issued from time to time
thereunder.
2.11 Controlled Affiliate means, with
respect to any person or entity, any other person or entity that
is controlled by such person or entity.
2.12 Committee means any committee of
the Board delegated responsibility by the Board for the
administration of the Plan, as provided in Section 5 of the
Plan. For any period during which no such committee is in
existence, the term Committee shall mean the
Board and all authority and responsibility assigned the
Committee under the Plan shall be exercised, if at all, by the
Board.
2.13 Common Stock means common stock,
par value $0.01 per share, of the Company.
2.14 Company means Amicus Therapeutics,
Inc., a corporation organized under the laws of the State of
Delaware.
2.15 Exchange Act means the Securities
Exchange Act of 1934, as amended.
2.16 Grant Date means the date as of
which an Option is granted, as determined under
Section 7.1(a).
2.17 Group has the meaning ascribed to
such term in Section 13(d)(3) of the Exchange Act or any
successor section thereto.
2.18 Incentive Option means an Option
which by its terms is to be treated as an incentive stock
option within the meaning of Section 422 of the Code.
2.19 Market Value means the value of a
share of Common Stock on a particular date determined by such
methods or procedures as may be established by the Committee.
Unless otherwise determined by the Committee, the Market Value
of Common Stock as of any date is the closing price for the
Common Stock as reported on the NASDAQ Global market (or on any
other national securities exchange on which the Common Stock is
then listed) for that date or, if no closing price is reported
for that date, the closing price on the next preceding date for
which a closing price was reported. For purposes of Awards
granted as of the effective date of the Companys initial
public offering, Market Value shall be the price at which the
Companys Common Stock is offered to the public in its
initial public offering.
2.20 Nonstatutory Option means any
Option that is not an Incentive Option.
2.21 Option means an option granted
under the Plan to purchase shares of Common Stock.
2.22 Optionee means an employee,
consultant or director of the Company to whom an Option shall
have been initially granted under the Plan.
2.23 Participant means any holder of an
outstanding Award under the Plan.
2.24 Plan means this 2007 Amended and
Restated Equity Incentive Plan of the Company, as amended and in
effect from time to time.
2.25 Restricted Stock means a grant or
sale pursuant to the Plan of shares of Common Stock to a
Participant subject to a Risk of Forfeiture.
2.26 Restricted Stock Units means rights
granted pursuant to the Plan to receive shares of Common Stock
at the close of a Restriction Period, subject to a Risk of
Forfeiture.
A-2
2.27 Restriction Period means the period
of time, established by the Committee in connection with an
Award of Restricted Stock or Restricted Stock Units, during
which the shares of Restricted Stock or Restricted Stock Units
are subject to a Risk of Forfeiture described in the applicable
Award Agreement.
2.28 Risk of Forfeiture means a
limitation on the right of a Participant to retain an Award of
Restricted Stock or Restricted Stock Units, including a right in
the Company to reacquire such Restricted Stock at less than its
then Market Value
and/or the
forfeiture of Restricted Stock Units held by a Participant,
arising because of the occurrence or non-occurrence of specified
events or conditions.
2.29 Sale of the Company Transaction
means any Transaction in which the stockholders of the Company
immediately prior to such Transaction, together with any and all
of such stockholders Affiliates, do not own or hold,
immediately after consummation of such Transaction, shares of
capital stock of the Acquiring Person in connection with such
Transaction possessing at least a majority of the total voting
power of the outstanding capital stock of such Acquiring Person.
2.30 Securities Act means the Securities
Act of 1933, as amended.
2.31 Stock Grant means the grant
pursuant to the Plan of shares of Common Stock not subject to
restrictions or other forfeiture conditions.
2.32 Ten Percent Owner means a
person who owns, or is deemed within the meaning of
Section 422(b)(6) of the Code to own, stock possessing more
than 10% of the total combined voting power of all classes of
stock of the Company (or any parent or subsidiary corporations
of the Company, as defined in Section 424(e) and (f),
respectively, of the Code). Whether a person is a Ten
Percent Owner shall be determined with respect to each
Option based on the facts existing immediately prior to the
Grant Date of such Option.
2.33 Transaction means any merger or
consolidation of the Company with or into another person or
entity or the sale or transfer of all or substantially all of
the assets of the Company, in each case in a single transaction
or in a series of related transactions.
Unless the Plan shall have been earlier terminated by the Board,
Awards may be granted under this Plan at any time in the period
commencing on the effective date of approval of the Plan by the
Board and ending immediately prior to the tenth anniversary of
the earlier of the adoption of the Plan by the Board or approval
of the Plan by the Companys stockholders. Awards granted
pursuant to the Plan within such period shall not expire solely
by reason of the termination of the Plan. Awards of Incentive
Options granted prior to stockholder approval of the Plan are
hereby expressly conditioned upon such approval, but in the
event of the failure of the stockholders to approve the Plan
shall thereafter and for all purposes be deemed to constitute
Nonstatutory Options.
|
|
4.
|
Stock
Subject to the Plan
|
Subject to the provisions of Section 8 of the Plan, at no
time shall the number of shares of Common Stock issued pursuant
to or subject to outstanding Awards granted under the Plan
(including, without limitation, pursuant to Incentive Options),
nor the number of shares of Common Stock issued pursuant to
Incentive Options, exceed the sum of (a) Two Million Nine
Hundred Sixty Six Thousand Six Hundred Sixty Seven (2,966,667)
shares of Common Stock. For purposes of applying the foregoing
limitation, if any Option expires, terminates, or is cancelled
for any reason without having been exercised in full, or if any
Award of Restricted Stock is forfeited, the shares not purchased
by the Participant or forfeited by the Participant shall again
be available for Awards thereafter to be granted under the Plan.
Shares of Common Stock issued pursuant to the Plan may be either
authorized but unissued shares or shares held by the Company in
its treasury.
In addition, not more than 300,000 of the total number of shares
of Common Stock reserved for issuance under the Plan (as
adjusted under Section 8) may be granted or sold as
Awards of Restricted Stock, Restricted Stock Units, Stock
Grants, and any other similar Awards (Full-Value
Awards) whose intrinsic value is not solely dependent on
appreciation in the price of Shares after the date of grant.
Options and any other similar Awards shall not be subject to,
and shall not count against, the limit described in the
preceding sentence. If a Full-Value Award expires, is
A-3
forfeited, or otherwise lapses as described in this
Section 4, the shares of Common Stock that were subject to
the Award shall be restored to the total number of shares of
Common Stock available for grant or sale as Full-Value Awards.
The Plan shall be administered by the Committee; provided,
however, that at any time and on any one or more occasions
the Board may itself exercise any of the powers and
responsibilities assigned the Committee under the Plan and when
so acting shall have the benefit of all of the provisions of the
Plan pertaining to the Committees exercise of its
authorities hereunder; and provided further that the
Committee may delegate to an executive officer or officers the
authority to grant Awards hereunder to employees who are not
officers, and to consultants, in accordance with such guidelines
as the Committee shall set forth at any time or from time to
time. Subject to the provisions of the Plan, the Committee shall
have complete authority, in its discretion, to make or to select
the manner of making all determinations with respect to each
Award to be granted by the Company under the Plan in addition to
any other determination allowed the Committee under the Plan
including, without limitation: (a) the employee, consultant
or director to receive the Award; (b) the form of Award;
(c) whether an Option (if granted to an employee) will be
an Incentive Option or a Nonstatutory Option; (d) the time
of granting an Award; (e) the number of shares subject to
an Award; (f) the exercise price of an Option or purchase
price, if any, for shares of Restricted Stock or for a Stock
Grant and the method of payment of such exercise price or such
purchase price; (g) the term of an Option; (h) the
vesting period of shares of Restricted Stock or of Restricted
Stock Units and any acceleration thereof; (i) the exercise
date or dates of an Option and any acceleration thereof; and
(j) the effect of termination of any employment, consulting
or Board member relationship with the Company or any of its
Affiliates on the subsequent exercisability of an Option or on
the Risk of Forfeiture of Restricted Stock or Restricted Stock
Units. In making such determinations, the Committee may take
into account the nature of the services rendered by the
respective employees, consultants and directors, their present
and potential contributions to the success of the Company and
its Affiliates, and such other factors as the Committee in its
discretion shall deem relevant. Subject to the provisions of the
Plan, the Committee shall also have complete authority to
interpret the Plan, to prescribe, amend and rescind rules and
regulations relating to it, to determine the terms and
provisions of the respective Award Agreements (which need not be
identical), and to make all other determinations necessary or
advisable for the administration of the Plan. The
Committees determinations made in good faith on matters
referred to in this Plan shall be final, binding and conclusive
on all persons having or claiming any interest under the Plan or
an Award made pursuant hereto.
|
|
6.
|
Authorization
and Eligibility
|
The Committee may grant from time to time and at any time prior
to the termination of the Plan one or more Awards, either alone
or in combination with any other Awards, to any employee of or
consultant to one or more of the Company and its Affiliates or
to any non-employee member of the Board or of any board of
directors (or similar governing authority) of any Affiliate.
However, only employees of the Company or of any parent or
subsidiary corporations of the Company, as defined in
Sections 424(e) and (f), respectively, of the Code, shall
be eligible for the grant of an Incentive Option. Further, in no
event shall the number of shares of Common Stock covered by
Options or other Awards granted to any one person in any one
calendar year (or portion of a year) ending after such date
exceed fifty percent (50%) of the aggregate number of shares of
Common Stock subject to the Plan.
Each grant of an Award shall be subject to all applicable terms
and conditions of the Plan (including but not limited to any
specific terms and conditions applicable to that type of Award
set out in the following Section), and such other terms and
conditions, not inconsistent with the terms of the Plan, as the
Committee may prescribe. No prospective Participant shall have
any rights with respect to an Award, unless and until such
Participant has executed an agreement evidencing the Award,
delivered a fully executed copy thereof to the Company, and
otherwise complied with the applicable terms and conditions of
such Award.
A-4
|
|
7.
|
Specific
Terms of Awards
|
7.1 Options.
(a) Date of Grant. The granting of an
Option shall take place at the time specified in the Award
Agreement. Only if expressly so provided in the applicable Award
Agreement shall the Grant Date be the date on which the Award
Agreement shall have been duly executed and delivered by the
Company and the Optionee.
(b) Exercise Price. The price at which
shares of Common Stock may be acquired under each Incentive
Option shall be not less than 100% of the Market Value of Common
Stock on the Grant Date, or not less than 110% of the Market
Value of Common Stock on the Grant Date if the Optionee is a Ten
Percent Owner. The price at which shares may be acquired
under each Nonstatutory Option shall not be so limited solely by
reason of this Section.
(c) Option Period. No Incentive Option or
Nonstatutory Option may be exercised on or after the tenth
anniversary of the Grant Date, or on or after the fifth
anniversary of the Grant Date if the Optionee is a Ten
Percent Owner.
(d) Exercisability. An Option may be
immediately exercisable or become exercisable in such
installments, cumulative or non-cumulative, as the Committee may
determine. In the case of an Option not otherwise immediately
exercisable in full, the Committee may Accelerate such Option in
whole or in part at any time; provided, however,
that in the case of an Incentive Option, any such
Acceleration of such Incentive Option would not cause such
Incentive Option to fail to comply with the provisions of
Section 422 of the Code or the Optionee consents to such
Acceleration.
(e) Effect of Termination of Employment, Consulting or
Board Member Relationship. Unless the Committee
shall provide otherwise with respect to any Option, if the
applicable Optionees association with the Company or any
of its Affiliates as an employee, director or consultant ends
for any reason or no reason, regardless of whether the end of
such association is effected by the Company, any such Affiliate
or such Optionee (whether voluntarily or involuntarily,
including because an entity with which such Optionee has any
such association ceases to be an Affiliate of the Company), and
immediately following the end of any such association, such
Optionee is not associated with the Company or any of its
Affiliates as an employee, director or consultant, or if such
Optionee dies, then any outstanding Option initially granted to
such Optionee, whether then held by such Optionee or any other
Participant, shall cease to be exercisable in any respect not
later than ninety (90) days following the end of such
association or such death and, for the period it remains
exercisable following the end of such association or such death,
shall be exercisable only to the extent exercisable on the date
of the end of such association or such death. Military or sick
leave or other bona fide leave shall not be deemed a termination
of employment, provided that it does not exceed the longer of
ninety (90) days or the period during which the absent
Optionees reemployment rights, if any, are guaranteed by
statute or by contract.
(f) Transferability. Except as otherwise
provided in this subsection (f), Options shall not be
transferable, and no Option or interest therein may be sold,
transferred, pledged, assigned, or otherwise alienated or
hypothecated, other than by will or by the laws of descent and
distribution (subject always to the provisions of
subsection (e) above). Except as otherwise provided in this
subsection (f), all of a Participants rights in any Option
may be exercised during the life of such Participant only by
such Participant or such Participants legal
representative. However, the applicable Award Agreement or the
Committee (at or after the grant of a Nonstatutory Option) may
provide that a Nonstatutory Option may be transferred by the
applicable Participant to a family member; provided, however,
that any such transfer is without payment of any consideration
whatsoever and that no transfer of a Nonstatutory Option shall
be valid unless first approved by the Committee, acting in its
sole discretion, unless such transfer is permitted under the
applicable Award Agreement. For this purpose, family
member means any child, stepchild, grandchild, parent,
stepparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law,
father-in-law,
son-in-law,
daughter-in-law,
brother-in-law,
or
sister-in-law,
including adoptive relationships, any person sharing the
applicable Participants household (other than a tenant or
employee), a trust in which the foregoing persons
and/or the
applicable Participant have more than fifty percent (50%) of the
beneficial interests, a foundation in which the foregoing
persons
and/or the
applicable Participant control the management of assets, and any
other entity in which these persons
and/or the
applicable Participant own more than fifty percent (50%) of the
voting interests. The Committee may at any time or from time to
time delegate to one or more officers of the
A-5
Company the authority to permit transfers of Nonstatutory
Options to third parties pursuant to this subsection (f), which
authorization shall be exercised by such officer or officers in
accordance with guidelines established by the Committee at any
time and from time to time. The restrictions on transferability
set forth in this subsection (f) shall in no way preclude
any Participant from effecting cashless exercises of
an Option pursuant to the terms of the Plan.
(g) Method of Exercise. An Option may be
exercised by a Participant giving written notice, in the manner
provided in Section 15, specifying the number of shares of
Common Stock with respect to which the Option is then being
exercised. The notice shall be accompanied by payment in the
form of cash or check payable to the order of the Company in an
amount equal to the exercise price of the shares of Common Stock
to be purchased or, subject in each instance to the
Committees approval, acting in its sole discretion and
subject to such conditions, if any, as the Committee may deem
necessary to comply with applicable laws, rules and regulations
or to avoid adverse accounting effects to the Company, by
delivery to the Company of (i) shares of Common Stock
having a Market Value equal to the exercise price of the shares
to be purchased, or (ii) the Participants executed
promissory note in the principal amount equal to the exercise
price of the shares to be purchased and otherwise in such form
as the Committee shall have approved. If the Common Stock is
traded on an established market, payment of any exercise price
may also be made through and under the terms and conditions of
any formal cashless exercise program authorized by the Company
entailing the sale of the Common Stock subject to any Option in
a brokered transaction (other than to the Company). Receipt by
the Company of such notice and payment in any authorized or
combination of authorized means shall constitute the exercise of
the Option. Within thirty (30) days thereafter but subject
to the remaining provisions of the Plan, the Company shall
deliver or cause to be delivered to the Participant or his agent
a certificate or certificates for the number of shares then
being purchased. Such shares shall be fully paid and
nonassessable. Notwithstanding any of the foregoing provisions
in this subsection (g) to the contrary, (A) no Option
shall be considered to have been exercised unless and until all
of the provisions governing such exercise specified in the Plan
and in the relevant Award Agreement shall have been duly
complied with; and (B) the obligation of the Company to
issue any shares upon exercise of an Option is subject to the
provisions of Section 9.1 hereof and to compliance by the
Optionee and the Participant with all of the provisions of the
Plan and the relevant Award Agreement.
(h) Limit on Incentive Option
Characterization. An Incentive Option shall be
considered to be an Incentive Option only to the extent that the
number of shares of Common Stock for which the Option first
becomes exercisable in a calendar year does not have an
aggregate Market Value (as of the date of the grant of the
Option) in excess of the current limit. The current
limit for any Optionee for any calendar year shall be $100,000
minus the aggregate Market Value at the date of grant of
the number of shares of Common Stock available for purchase for
the first time in the same year under each other Incentive
Option previously granted to the Optionee under the Plan, and
under each other incentive stock option previously granted to
the Optionee under any other incentive stock option plan of the
Company and its Affiliates, after December 31, 1986. Any
shares of Common Stock which would cause the foregoing limit to
be violated shall be deemed to have been granted under a
separate Nonstatutory Option, otherwise identical in its terms
to those of the Incentive Option.
(i) Notification of Disposition. Each
person exercising any Incentive Option granted under the Plan
shall be deemed to have covenanted with the Company to report to
the Company any disposition of such shares prior to the
expiration of the holding periods specified by
Section 422(a)(1) of the Code and, if and to the extent
that the realization of income in such a disposition imposes
upon the Company federal, state, local or other withholding tax
requirements, or any such withholding is required to secure for
the Company an otherwise available tax deduction, to remit to
the Company an amount in cash sufficient to satisfy those
requirements.
(j) Rights Pending Exercise. No person
holding an Option shall be deemed for any purpose to be a
stockholder of the Company with respect to any of the shares of
Common Stock issuable pursuant to such Option, except to the
extent that such Option shall have been exercised with respect
thereto and, in addition, a certificate shall have been issued
therefor and delivered to such person or his agent.
7.2 Restricted Stock.
(a) Purchase Price. Shares of Restricted
Stock shall be issued under the Plan for such consideration, in
cash, other property or services, or any combination thereof, as
is determined by the Committee.
A-6
(b) Issuance of Certificates. Subject to
subsection (c) below, each Participant receiving an Award
of Restricted Stock shall be issued a stock certificate in
respect of such shares of Restricted Stock. Such certificate
shall be registered in the name of such Participant, and, if
applicable, shall bear an appropriate legend referring to the
terms, conditions, and restrictions applicable to such Award
substantially in the following form:
The transferability of this certificate and the shares
represented by this certificate are subject to the terms and
conditions of the Amicus Therapeutics, Inc. Amended and Restated
2007 Equity Incentive Plan and an Award Agreement entered into
by the registered owner and Amicus Therapeutics, Inc. Copies of
such Plan and Agreement are on file in the offices of Amicus
Therapeutics, Inc.
(c) Escrow of Shares. The Committee may
require that the stock certificates evidencing shares of
Restricted Stock be held in custody by a designated escrow agent
(which may but need not be the Company) until the restrictions
thereon shall have lapsed, and that the Participant deliver a
stock power, endorsed in blank, relating to the Common Stock
covered by such Award.
(d) Restrictions and Restriction
Period. During the Restriction Period applicable
to shares of Restricted Stock, such shares shall be subject to
limitations on transferability and a Risk of Forfeiture arising
on the basis of such conditions related to the performance of
services, Company or Affiliate performance or otherwise as the
Committee may determine and provide for in the applicable Award
Agreement. Any such Risk of Forfeiture may be waived or
terminated, or the Restriction Period shortened, at any time by
the Committee on such basis as it deems appropriate.
(e) Rights Pending Lapse of Risk of Forfeiture or
Forfeiture of Award. Except as otherwise provided
in the Plan or the applicable Award Agreement, at all times
prior to lapse of any Risk of Forfeiture applicable to, or
forfeiture of, an Award of Restricted Stock, the Participant
shall have all of the rights of a stockholder of the Company,
including the right to vote the shares of Restricted Stock.
(f) Effect of Termination of Employment, Consulting or
Board Member Relationship. Unless otherwise
determined by the Committee at or after grant and subject to the
applicable provisions of the Award Agreement, if the applicable
original grantees association with the Company or any of
its Affiliates as an employee, director or consultant ends for
any reason or no reason during the Restriction Period,
regardless of whether the end of such association is effected by
the Company, any such Affiliate or such original grantee
(whether voluntarily or involuntarily, including because an
entity with which such original grantee has any such association
ceases to be an Affiliate of the Company), and immediately
following the end of any such association, such original grantee
is not associated with the Company or any of its Affiliates as
an employee, director or consultant, or if such original grantee
dies, then all outstanding shares of Restricted Stock initially
granted to such original grantee that are still subject to Risk
of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to
return to or repurchase by the Company if and to the extent so
provided by, and subject to and in accordance with, the terms of
the applicable Award Agreement; provided, however, that military
or sick leave or other bona fide leave shall not be deemed a
termination of employment, if it does not exceed the longer of
ninety (90) days or the period during which the absent
original grantees reemployment rights, if any, are
guaranteed by statute or by contract.
(g) Lapse of Restrictions. If and when
the Restriction Period expires without a prior forfeiture of the
Restricted Stock, the certificates for such shares shall be
delivered to the Participant promptly if not theretofore so
delivered.
(h) Transferability. Except as otherwise
provided in this subsection (h), shares of Restricted Stock
shall not be transferable, and no share of Restricted Stock or
interest therein may be sold, transferred, pledged, assigned, or
otherwise alienated or hypothecated, other than by will or by
the laws of descent and distribution (subject always to the
provisions of subsection (f) above). The applicable Award
Agreement or the Committee (at or after the grant of a share of
Restricted Stock) may provide that such share of Restricted
Stock may be transferred by the applicable Participant to a
family member; provided, however, that any such transfer is
without payment of any consideration whatsoever and that no
transfer of a share of Restricted Stock shall be valid unless
first approved by the Committee, acting in its sole discretion,
unless such transfer is permitted under the applicable Award
Agreement. For this purpose, family member means any
child, stepchild, grandchild, parent, stepparent, spouse, former
spouse,
A-7
sibling, niece, nephew,
mother-in-law,
father-in-law,
son-in-law,
daughter-in-law,
brother-in-law,
or
sister-in-law,
including adoptive relationships, any person sharing the
applicable Participants household (other than a tenant or
employee), a trust in which the foregoing persons
and/or the
applicable Participant have more than fifty percent (50%) of the
beneficial interests, a foundation in which the foregoing
persons
and/or the
applicable Participant control the management of assets, and any
other entity in which these persons
and/or the
applicable Participant own more than fifty percent (50%) of the
voting interests. The Committee may at any time or from time to
time delegate to one or more officers of the Company the
authority to permit transfers of shares of Restricted Stock to
third parties pursuant to this subsection (h), which
authorization shall be exercised by such officer or officers in
accordance with guidelines established by the Committee at any
time and from time to time.
7.3. Restricted Stock Units.
(a) Character. Each Restricted Stock Unit
shall entitle the recipient to a share of Common Stock at a
close of such Restriction Period as the Committee may establish
and subject to a Risk of Forfeiture arising on the basis of such
conditions relating to the performance of services, Company or
Affiliate performance or otherwise as the Committee may
determine and provide for in the applicable Award Agreement. Any
such Risk of Forfeiture may be waived or terminated, or the
Restriction Period shortened, at any time by the Committee on
such basis as it deems appropriate.
(b) Issuance of Certificates. Unless
otherwise determined by the Committee at or after grant and
subject to the applicable provisions of the Award Agreement, at
the close of the Restriction Period applicable to any Restricted
Stock Units (including, without limitation, the close of the
applicable Restriction Period as a result of (i) any
Acceleration of Restricted Stock Units in accordance with the
terms of this Plan or any applicable Award Agreement,
(ii) any waiver, lapse or termination of the Risk of
Forfeiture applicable to Restricted Stock Units in accordance
with the terms of this Plan or any applicable Award Agreement or
(iii) any shortening of the Restriction Period applicable
to any Restricted Stock Units in accordance with the terms of
this Plan or any applicable Award Agreement), the Company shall
deliver or cause to be delivered to the Participant that is the
holder of such Restricted Stock Units a stock certificate in
respect of the shares of Common Stock subject to such Restricted
Stock Units. Such certificate shall be registered in the name of
such Participant, and, if applicable, shall bear an appropriate
legend referring to the terms, conditions, and restrictions
applicable to such shares of Common Stock substantially in the
following form:
The transferability of this certificate and the shares
represented by this certificate are subject to the terms and
conditions of the Amicus Therapeutics, Inc. Amended and Restated
2007 Equity Incentive Plan and an Award Agreement entered into
by the registered owner and Amicus Therapeutics, Inc. Copies of
such Plan and Agreement are on file in the offices of Amicus
Therapeutics, Inc.
(c) Dividends. At the discretion of the
Committee, Participants may be entitled to receive payments
equivalent to any dividends declared with respect to Common
Stock referenced in grants of Restricted Stock Units but only
following the close of the applicable Restriction Period and
then only if the underlying Common Stock shall have been earned.
Unless the Committee shall provide otherwise, any such dividend
equivalents shall be paid, if at all, without interest or other
earnings.
(d) Effect of Termination of Employment, Consulting or
Board Member Relationship. Unless otherwise
determined by the Committee at or after grant and subject to the
applicable provisions of the Award Agreement, if the applicable
original grantees association with the Company or any of
its Affiliates as an employee, director or consultant ends for
any reason or no reason during the Restriction Period,
regardless of whether the end of such association is effected by
the Company, any such Affiliate or such original grantee
(whether voluntarily or involuntarily, including because an
entity with which such original grantee has any such association
ceases to be an Affiliate of the Company), and immediately
following the end of any such association, such original grantee
is not associated with the Company or any of its Affiliates as
an employee, director or consultant, or if such original grantee
dies, then all outstanding Restricted Stock Units initially
granted to such original grantee that are still subject to Risk
of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to
return to the Company in accordance with the terms of the
applicable Award Agreement; provided, however, that military or
sick leave or other bona fide leave shall not be deemed a
termination of
A-8
employment, if it does not exceed the longer of ninety
(90) days or the period during which the absent original
grantees reemployment rights, if any, are guaranteed by
statute or by contract.
(e) Transferability. Except as otherwise
provided in this subsection (e), Restricted Stock Units shall
not be transferable, and no Restricted Stock Unit or interest
therein may be sold, transferred, pledged, assigned, or
otherwise alienated or hypothecated. The applicable Award
Agreement or the Committee (at or after the grant of a
Restricted Stock Unit) may provide that such Restricted Stock
Unit may be transferred by the applicable Participant to a
family member; provided, however, that any such transfer is
without payment of any consideration whatsoever and that no
transfer of a Restricted Stock Unit shall be valid unless first
approved by the Committee, acting in its sole discretion, unless
such transfer is permitted under the applicable Award Agreement.
For this purpose, family member means any child,
stepchild, grandchild, parent, stepparent, spouse, former
spouse, sibling, niece, nephew,
mother-in-law,
father-in-law,
son-in-law,
daughter-in-law,
brother-in-law,
or
sister-in-law,
including adoptive relationships, any person sharing the
applicable Participants household (other than a tenant or
employee), a trust in which the foregoing persons
and/or the
applicable Participant have more than fifty percent (50%) of the
beneficial interests, a foundation in which the foregoing
persons
and/or the
applicable Participant control the management of assets, and any
other entity in which these persons
and/or the
applicable Participant own more than fifty percent (50%) of the
voting interests. The Committee may at any time or from time to
time delegate to one or more officers of the Company the
authority to permit transfers of Restricted Stock Units to third
parties pursuant to this subsection (e), which authorization
shall be exercised by such officer or officers in accordance
with guidelines established by the Committee at any time and
from time to time.
(f) Rights Pending Close of Applicable Restriction
Period. No person holding Restricted Stock Units
shall be deemed for any purpose to be a stockholder of the
Company with respect to any of the shares of Common Stock
subject to such Restricted Stock Units, except to the extent
that the Restricted Period with respect to such Restricted Stock
Units shall have closed and, in addition, a certificate shall
have been issued for such shares of Common Stock and delivered
to such person or his agent. Shares of Common Stock subject to
Restricted Stock Units shall be issued and outstanding only if
and to the extent that a stock certificate representing such
shares has been issued and delivered in accordance with the
provisions of this Section 7.3.
7.4. Stock Grants.
(a) In General. Stock Grants shall be
issued for such consideration, in cash, other property or
services, or any combination thereof, as is determined by the
Committee. Without limiting the generality of the foregoing,
Stock Grants may be awarded in such circumstances as the
Committee deems appropriate, including without limitation in
recognition of significant contributions to the success of the
Company or its Affiliates or in lieu of compensation otherwise
already due. Stock Grants shall be made without forfeiture
conditions of any kind.
(b) Issuance of Certificates. Each
Participant receiving a Stock Grant shall be issued a stock
certificate in respect of such Stock Grant. Such certificate
shall be registered in the name of such Participant, and, if
applicable, shall bear an appropriate legend referring to the
terms, conditions, and restrictions applicable to such Award
substantially in the following form:
The transferability of this certificate and the shares
represented by this certificate are subject to the terms and
conditions of the Amicus Therapeutics, Inc. 2007 Equity
Incentive Plan. A copy of such Plan is on file in the offices of
Amicus Therapeutics, Inc.
7.5. Awards to Participants Outside the United
States. The Committee may modify the terms of any
Award under the Plan granted to a Participant who is, at the
time of grant or during the term of the Award, resident or
primarily employed outside of the United States in any manner
deemed by the Committee to be necessary or appropriate in order
that such Award shall conform to laws, regulations, and customs
of the country in which the Participant is then resident or
primarily employed, or so that the value and other benefits of
the Award to the Participant, as affected by foreign tax laws
and other restrictions applicable as a result of the
Participants residence or employment abroad, shall be
comparable to the value of such an Award to a Participant who is
resident or primarily employed in the United States. An Award
may be modified under this Section 7.4 in a manner that is
inconsistent with the express terms of the Plan, so long as such
modifications will not contravene any applicable law or
regulation. The Committee may establish supplements to, or
amendments, restatements, or alternative versions of
A-9
the Plan for the purpose of granting and administrating any such
modified Award. No such modification, supplement, amendment,
restatement or alternative version may increase the share limit
of Section 4.
8.1 Adjustment for Corporate Actions. All
of the share numbers set forth in the Plan reflect the capital
structure of the Company immediately after the closing of the
initial public offering of the Companys Common Stock.
Subject to the provisions of Section 8.2, if subsequent to
such closing the outstanding shares of Common Stock (or any
other securities covered by the Plan by reason of the prior
application of this Section) are increased, decreased, or
exchanged for a different number or kind of shares or other
securities, or if additional shares or new or different shares
or other securities are distributed with respect to such shares
of Common Stock or other securities, through merger,
consolidation, sale of all or substantially all the property of
the Company, reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, or other
distribution with respect to such shares of Common Stock, or
other securities, an appropriate and proportionate adjustment
will be made in (i) the maximum numbers and kinds of shares
provided in Section 4, (ii) the numbers and kinds of
shares or other securities subject to the then outstanding
Awards, (iii) the exercise price for each share or other
unit of any other securities subject to then outstanding Options
(without change in the aggregate purchase price as to which such
Options remain exercisable), and (iv) the repurchase price
of each share of Restricted Stock then subject to a Risk of
Forfeiture in the form of a Company repurchase right.
8.2. Change of Control. Subject to the
applicable provisions of the Award Agreement, in the event of a
Change of Control, the Committee shall have the discretion,
exercisable in advance of, at the time of, or (except to the
extent otherwise provided below) at any time after, the Change
of Control, to provide for any or all of the following (subject
to and upon such terms as the Committee may deem appropriate):
(A) the Acceleration, in whole or in part, of any or all
outstanding Options (including Options that are assumed or
replaced pursuant to clause (D) below) that are not
exercisable in full at the time the Change of Control, such
Acceleration to become effective at the time of the Change of
Control, or at such time following the Change of Control that
the employment, consulting or Board member relationship of the
applicable Optionee or Optionees with the Company and its
Affiliates terminates, or at such other time or times as the
Committee shall determine; (B) the lapse or termination of
the Risk of Forfeiture (including, without limitation, any or
all of the Companys repurchase rights) with respect to
outstanding Awards of Restricted Stock, such lapse or
termination to become effective at the time of the Change of
Control, or at such time following the Change of Control that
the employment, consulting or Board member relationship with the
Company and its Affiliates of the Participant or Participants
that hold such Awards of Restricted Stock (or the person to whom
such Awards of Restricted Stock were initially granted)
terminates, or at such other time or times as the Committee
shall determine; (C) the lapse or termination of the Risk
of Forfeiture with respect to any or all outstanding Awards of
Restricted Stock Units (including Restricted Stock Units that
are assumed or replaced pursuant to clause (D) below), such
lapse or termination to become effective at the time of the
Change of Control, or at such time following the Change of
Control that the employment, consulting or Board member
relationship with the Company and its Affiliates of the
Participant or Participants that hold such Awards of Restricted
Stock Units (or the person to whom such Awards of Restricted
Stock Units were initially granted) terminates, or at such other
time or times as the Committee shall determine; (D) the
assumption of outstanding Options or Restricted Stock Units, or
the substitution of outstanding Options or Restricted Stock
Units with equivalent options or equivalent restricted stock
units, as the case may be, by the acquiring or succeeding
corporation or entity (or an affiliate thereof); (E) the
termination of all Options (other than Options that are assumed
or substituted pursuant to clause (D) above) that remain
outstanding at the time of the consummation of the Change of
Control, provided that, the Committee shall have made the
determination to effect such termination prior to the
consummation of the Change of Control and the Committee shall
have given, or caused to be given, to all Participants written
notice of such potential termination at least five business days
prior to the consummation of the Change of Control, and
provided, further, that, if the Committee shall have determined
in its sole and absolute discretion that the Corporation make
payment or provide consideration to the holders of such
terminated Options on account of such termination, which payment
or consideration shall be on such terms and conditions as the
Committee shall have determined (and which could consist of, in
the Committees sole and absolute discretion, payment to
the applicable Optionee or Optionees of an amount of cash equal
to the difference between the Market Value of the shares of
Common Stock for which the Option is then exercisable and the
aggregate exercise price for such shares under the Option), then
the Corporation shall be
A-10
required to make, or cause to be made, such payment or provide,
or cause to be provided, such consideration in accordance with
the terms and conditions so determined by the Committee,
otherwise the Corporation shall not be required to make any
payment or provide any consideration in connection with, or as a
result of, the termination of Options pursuant to the foregoing
provisions of this clause (E); or (F) the termination of
all Restricted Stock Units (other than Restricted Stock Units
that are assumed or substituted pursuant to clause (D)
above) that remain outstanding at the time of the consummation
of the Change of Control, provided that, if the Committee shall
have determined in its sole and absolute discretion that the
Corporation make payment or provide consideration to the holders
of such terminated Restricted Stock Units on account of such
termination, which payment or consideration shall be on such
terms and conditions as the Committee shall have determined (and
which could consist of, in the Committees sole and
absolute discretion, payment to the applicable Participant or
Participants of an amount of cash equal to the Market Value of
the shares of Common Stock subject to the terminated Restricted
Stock Units), then the Corporation shall be required to make
such payment or provide such consideration in accordance with
the terms and conditions so determined by the Committee,
otherwise the Corporation shall not be required to make any
payment or provide any consideration in connection with, or as a
result of, the termination of Restricted Stock Units pursuant to
the foregoing provisions of this clause (F). The provisions of
this Section 8.2 shall not be construed as to limit or
restrict in any way the Committees general authority under
Sections 7.1(d) or 7.2(d) hereof to Accelerate Options in
whole or in part at any time or to waive or terminate at any
time any Risk of Forfeiture applicable to shares of Restricted
Stock or Restricted Stock Units. Each outstanding Option or
Restricted Stock Unit that is assumed in connection with a
Change of Control, or is otherwise to continue in effect
subsequent to a Change of Control, will be appropriately
adjusted, immediately after the Change of Control, as to the
number and class of securities and the price at which it may be
exercised in accordance with Section 8.1.
8.3. Dissolution or Liquidation. Upon
dissolution or liquidation of the Company, each outstanding
Option shall terminate, but the Optionee (if at the time he or
she has an employment, consulting or Board member relationship
with the Company or any of its Affiliates) shall have the right,
immediately prior to such dissolution or liquidation, to
exercise the Option to the extent exercisable on the date of
such dissolution or liquidation.
8.4. Related Matters. Any adjustment in
Awards made pursuant to this Section 8 shall be determined
and made, if at all, by the Committee and shall include any
correlative modification of terms, including of Option exercise
prices, rates of vesting or exercisability, Risks of Forfeiture
and applicable repurchase prices for Restricted Stock, which the
Committee may deem necessary or appropriate so as to ensure that
the rights of the Participants in their respective Awards are
not substantially diminished nor enlarged as a result of the
adjustment and corporate action other than as expressly
contemplated in this Section 8. No fraction of a share
shall be purchasable or deliverable upon exercise, but in the
event any adjustment hereunder of the number of shares covered
by an Award shall cause such number to include a fraction of a
share, such number of shares shall be adjusted to the nearest
smaller whole number of shares. No adjustment of an Option
exercise price per share pursuant to this Section 8 shall
result in an exercise price which is less than the par value of
the Common Stock.
9.1 Violation of Law. Notwithstanding any
other provision of the Plan or the relevant Award Agreement, if,
at any time, in the reasonable opinion of the Company, the
issuance of shares of Common Stock covered by an Award may
constitute a violation of law, then the Company may delay such
issuance and the delivery of a certificate for such shares until
(i) approval shall have been obtained from such
governmental agencies, other than the Securities and Exchange
Commission, as may be required under any applicable law, rule,
or regulation and (ii) in the case where such issuance
would constitute a violation of a law administered by or a
regulation of the Securities and Exchange Commission, one of the
following conditions shall have been satisfied:
(a) the shares are at the time of the issue of such shares
effectively registered under the Securities Act; or
(b) the Company shall have determined, on such basis as it
deems appropriate (including an opinion of counsel in form and
substance satisfactory to the Company) that the sale, transfer,
assignment, pledge, encumbrance or other disposition of such
shares or such beneficial interest, as the case may be, does not
require registration under the Securities Act or any applicable
state securities laws.
A-11
9.2 Corporate Restrictions on Rights in
Stock. Any Common Stock to be issued pursuant to
Awards granted under the Plan shall be subject to all
restrictions upon the transfer thereof which may be now or
hereafter imposed by the Certificate of Incorporation and the
By-laws of the Company, each as amended and in effect from time
to time. Whenever Common Stock is to be issued pursuant to an
Award, if the Committee so directs at the time of grant (or, if
such Award is an Option, at any time prior to the exercise
thereof), the Company shall be under no obligation,
notwithstanding any other provision of the Plan or the relevant
Award Agreement to the contrary, to issue such shares until such
time, if ever, as the recipient of the Award (and any person who
exercises any Option, in whole or in part), shall have become a
party to and bound by any agreement that the Committee shall
require in its sole discretion. In addition, any Common Stock to
be issued pursuant to Awards granted under the Plan shall be
subject to all stop-transfer orders and other restrictions as
the Committee may deem advisable under the rules, regulations
and other requirements of any stock exchange upon which the
Common Stock is then listed, and any applicable federal or state
securities laws, and the Committee may cause a legend or legends
to be put on any such certificates to make appropriate reference
to such restrictions.
9.3 Investment Representations. The
Company shall be under no obligation to issue any shares covered
by an Award unless the shares to be issued pursuant to Awards
granted under the Plan have been effectively registered under
the Securities Act or the Participant shall have made such
written representations to the Company (upon which the Company
believes it may reasonably rely) as the Company may deem
necessary or appropriate for purposes of confirming that the
issuance of such shares will be exempt from the registration
requirements of that Act and any applicable state securities
laws and otherwise in compliance with all applicable laws, rules
and regulations, including but not limited to that the
Participant is acquiring shares for his or her own account for
the purpose of investment and not with a view to, or for sale in
connection with, the distribution of any such shares.
9.4 Registration. If the Company shall
deem it necessary or desirable to register under the Securities
Act or other applicable statutes any shares of Common Stock
issued or to be issued pursuant to Awards granted under the
Plan, or to qualify any such shares of Common Stock for
exemption from the Securities Act or other applicable statutes,
then the Company shall take such action at its own expense. The
Company may require from each recipient of an Award, or each
holder of shares of Common Stock acquired pursuant to the Plan,
such information in writing for use in any registration
statement, prospectus, preliminary prospectus or offering
circular as is reasonably necessary for such purpose and may
require reasonable indemnity to the Company and its officers and
directors from such holder against all losses, claims, damage
and liabilities arising from such use of the information so
furnished and caused by any untrue statement of any material
fact therein or caused by the omission to state a material fact
required to be stated therein or necessary to make the
statements therein not misleading in the light of the
circumstances under which they were made.
9.5 Lock-Up. Without
the prior written consent of the Company or the managing
underwriter in any public offering of shares of Common Stock, no
Participant shall sell, make any short sale of, loan, grant any
option for the purchase of, pledge or otherwise encumber, or
otherwise dispose of, any shares of Common Stock during the one
hundred-eighty (180) day period commencing on the effective
date of the registration statement relating to any underwritten
public offering of securities of the Company. The foregoing
restrictions are intended and shall be construed so as to
preclude any Participant from engaging in any hedging or other
transaction that is designed to or reasonably could be expected
to lead to or result in, a sale or disposition of any shares of
Common Stock during such period even if such shares of Common
Stock are or would be disposed of by someone other than such
Participant. Such prohibited hedging or other transactions would
include, without limitation, any short sale (whether or not
against the box) or any purchase, sale or grant of any right
(including without limitation any put or call option) with
respect to any shares of Common Stock or with respect to any
security that includes, relates to, or derives any significant
part of its value from any shares of Common Stock. Without
limiting the generality of the foregoing provisions of this
Section 9.5, if, in connection with any underwritten public
offering of securities of the Company, the managing underwriter
of such offering requires that the Companys directors and
officers enter into a
lock-up
agreement containing provisions that are more restrictive than
the provisions set forth in the preceding sentence, then
(a) each Participant (regardless of whether or not such
Participant has complied or complies with the provisions of
clause (b) below) shall be bound by, and shall be deemed to
have agreed to, the same
lock-up
terms as those to which the Companys directors and
officers are required to adhere; and (b) at the request of
the Company or such
A-12
managing underwriter, each Participant shall execute and deliver
a lock-up
agreement in form and substance equivalent to that which is
required to be executed by the Companys directors and
officers.
9.6 Placement of Legends; Stop Orders;
Etc. Each share of Common Stock to be issued
pursuant to Awards granted under the Plan may bear a reference
to the investment representations made in accordance with
Section 9.3 in addition to any other applicable
restrictions under the Plan, the terms of the Award and, if
applicable, under any agreement between the Company and any
Optionee
and/or
Participant, and to the fact that no registration statement has
been filed with the Securities and Exchange Commission in
respect to such shares of Common Stock. All certificates for
shares of Common Stock or other securities delivered under the
Plan shall be subject to such stock transfer orders and other
restrictions as the Committee may deem advisable under the
rules, regulations, and other requirements of any stock exchange
upon which the Common Stock is then listed, and any applicable
federal or state securities law, and the Committee may cause a
legend or legends to be placed on any such certificates to make
appropriate reference to such restrictions.
9.7 Tax Withholding. Whenever shares of
Common Stock are issued or to be issued pursuant to Awards
granted under the Plan, the Company shall have the right to
require the recipient to remit to the Company an amount
sufficient to satisfy federal, state, local or other withholding
tax requirements if, when, and to the extent required by law
(whether so required to secure for the Company an otherwise
available tax deduction or otherwise) prior to the delivery of
any certificate or certificates for such shares. The obligations
of the Company under the Plan shall be conditional on
satisfaction of all such withholding obligations and the Company
shall, to the extent permitted by law, have the right to deduct
any such taxes from any payment of any kind otherwise due to the
recipient of an Award. However, in such cases Participants may
elect, subject to the approval of the Committee, acting in its
sole discretion, to satisfy an applicable withholding
requirements, in whole or in part, by having the Company
withhold shares to satisfy their tax obligations. Participants
may only elect to have shares of their Common Stock withheld
having a Market Value on the date the tax is to be determined
equal to the minimum statutory total tax which could be imposed
on the transaction. All elections shall be irrevocable, made in
writing, signed by the Participant, and shall be subject to any
restrictions or limitation that the Committee deems appropriate.
The Company shall at all times during the term of the Plan and
any outstanding Options granted hereunder reserve or otherwise
keep available such number of shares of Common Stock as will be
sufficient to satisfy the requirements of the Plan (if then in
effect) and such Options and shall pay all fees and expenses
necessarily incurred by the Company in connection therewith.
|
|
11.
|
No
Special Service Rights
|
Nothing contained in the Plan or in any Award Agreement shall
confer upon any recipient of an Award any right with respect to
the continuation of his or her employment, consulting or Board
member relationship or other association with the Company (or
any Affiliate), or interfere in any way with the right of the
Company (or any Affiliate), subject to the terms of any separate
employment, consulting or Board member agreement or provision of
law or corporate articles or by-laws to the contrary, at any
time to terminate such employment, consulting or Board member
agreement or to increase or decrease, or otherwise adjust, the
other terms and conditions of the recipients employment,
consulting or Board member relationship or other association
with the Company and its Affiliates.
|
|
12.
|
Nonexclusivity
of the Plan
|
Neither the adoption of the Plan by the Board nor the submission
of the Plan to the stockholders of the Company shall be
construed as creating any limitations on the power of the Board
to adopt such other incentive arrangements as it may deem
desirable, including without limitation, the granting of stock
options, restricted stock and restricted stock units other than
under the Plan, and such arrangements may be either applicable
generally or only in specific cases.
A-13
|
|
13.
|
Termination
and Amendment of the Plan
|
The Board may at any time terminate the Plan or make such
amendments or modifications of the Plan as it shall deem
advisable. In the event of the termination of the Plan, the
terms of the Plan shall survive any such termination with
respect to any Award that is outstanding on the date of such
termination, unless the holder of such Award agrees in writing
to terminate such Award or to terminate all or any of the
provisions of the Plan that apply to such Award. Unless the
Board otherwise expressly provides, any amendment or
modification of the Plan shall affect the terms of any Award
outstanding on the date of such amendment or modification as
well as the terms of any Award made from and after the date of
such amendment or modification; provided, however, that,
except to the extent otherwise provided in the last sentence of
this paragraph, (i) no amendment or modification of the
Plan shall apply to any Award that is outstanding on the date of
such amendment or modification if such amendment or modification
would reduce the number of shares subject to such Award,
increase the purchase price applicable to shares subject to such
Award or materially adversely affect the provisions applicable
to such Award that relate to the vesting or exercisability of
such Award or of the shares subject to such Award, (ii) no
amendment or modification of the Plan shall apply to any
Incentive Option that is outstanding on the date of such
amendment or modification if such amendment or modification
would result in such Incentive Option no longer being treated as
an incentive stock option within the meaning of
Section 422 of the Code and (iii) no amendment or
modification of the Plan shall apply to any Award that is
outstanding on the date of such amendment or modification unless
such amendment or modification of the Plan shall also apply to
all other Awards outstanding on the date of such amendment or
modification. In the event of any amendment or modification of
the Plan that is described in clause (i), (ii) or
(iii) of the foregoing proviso, such amendment or
modification of the Plan shall apply to any Award outstanding on
the date of such amendment or modification only if the recipient
of such Award consents in writing thereto.
The Committee may amend or modify, prospectively or
retroactively, the terms of any outstanding Award without
amending or modifying the terms of the Plan itself, provided
that as amended or modified such Award is consistent with
the terms of the Plan as in effect at the time of the amendment
or modification of such Award, but no such amendment or
modification of such Award shall, without the written consent of
the recipient of such Award, reduce the number of shares subject
to such Award, increase the purchase price applicable to shares
subject to such Award, adversely affect the provisions
applicable to such Award that relate to the vesting or
exercisability of such Award or of the shares subject to such
Award, or otherwise materially adversely affect the terms of
such Award (except for amendments or modifications to the terms
of such Award or of the stock subject to such Award that are
expressly permitted by the terms of the Plan or that result from
any amendment or modification of the Plan in accordance with the
provisions of the first paragraph of this Section 13), or,
if such Award is an Incentive Option, result in such Incentive
Option no longer being treated as an incentive stock
option within the meaning of Section 422 of the Code.
Notwithstanding any of the foregoing provisions of this
paragraph to the contrary, the Committee is expressly authorized
to amend any or all outstanding Options to effect a repricing
thereof by lowering the purchase price applicable to the shares
of Common Stock subject to such Option or Options without the
approval of the stockholders of the Company or the holder or
holders of such Option or Options, and, in connection with such
repricing, to amend or modify any of the other terms of the
Option or Options so repriced, including, without limitation,
for purposes of reducing the number of shares subject to such
Option or Options or for purposes of adversely affecting the
provisions applicable to such Option or Options that relate to
the vesting or exercisability thereof, in each case without the
approval of stockholders of the Company or the holder or holders
of such Option or Options.
In addition, notwithstanding anything express or implied in any
of the foregoing provisions of this Section 13 to the
contrary, the Committee may amend or modify, prospectively or
retroactively, the terms of any outstanding Award to the extent
the Committee reasonably determines necessary or appropriate to
conform such Award to the requirements of Section 409A of
the Code (concerning non-qualified deferred compensation), if
applicable.
|
|
14.
|
Interpretation
of the Plan
|
In the event of any conflict between the provisions of this Plan
and the provisions of any applicable Award Agreement, the
provisions of this Plan shall control, except if and to the
extent that the conflicting provision in such Award Agreement
was authorized and approved by the Committee at the time of the
grant of the Award evidenced by such Award Agreement or is
ratified by the Committee at any time subsequent to the grant of
such Award, in
A-14
which case the conflicting provision in such Award Agreement
shall control. Without limiting the generality of the foregoing
provisions of this Section 14, insofar as possible the
provisions of the Plan and such Award Agreement shall be
construed so as to give full force and effect to all such
provisions. In the event of any conflict between the provisions
of this Plan and the provisions of any other agreement between
the Company and the Optionee
and/or
Participant, the provisions of such agreement shall control
except as required to fulfill the intention that this Plan
constitute an incentive stock option plan within the meaning of
Section 422 of the Code, but insofar as possible the
provisions of the Plan and any such agreement shall be construed
so as to give full force and effect to all such provisions.
|
|
15.
|
Notices
and Other Communications
|
Any notice, demand, request or other communication hereunder to
any party shall be deemed to be sufficient if contained in a
written instrument delivered in person or duly sent by first
class registered, certified or overnight mail, postage prepaid,
or telecopied with a confirmation copy by regular, certified or
overnight mail, addressed or telecopied, as the case may be,
(i) if to the recipient of an Award, at his or her
residence address last filed with the Company and (ii) if
to the Company, at its principal place of business, addressed to
the attention of its Chief Executive Officer, or to such other
address or telecopier number, as the case may be, as the
addressee may have designated by notice to the addressor. All
such notices, requests, demands and other communications shall
be deemed to have been received: (i) in the case of
personal delivery, on the date of such delivery; (ii) in
the case of mailing, when received by the addressee; and
(iii) in the case of facsimile transmission, when confirmed
by facsimile machine report.
The Plan and all Award Agreements and actions taken thereunder
shall be governed, interpreted and enforced in accordance with
the laws of the State of New Jersey, without regard to the
conflict of laws principles thereof.
A-15
ANNUAL MEETING OF STOCKHOLDERS OF
Amicus Therapeutics, Inc
June 10, 2008
Please sign, date and mail
your proxy card in the
envelope provided as soon
as possible.
ê
Please detach along perforated line and mail in the envelope provided.
ê
|
|
|
n 20330300000000000000 3
|
|
061008 |
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE
ELECTION OF DIRECTORS AND FOR PROPOSALS 2 AND 3.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE
x
1. |
|
Election of Directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOMINEES: |
|
|
o
|
|
FOR ALL NOMINEES
|
|
¡ ¡
|
|
Alexander E. Barkas Stephen Bloch |
|
|
|
|
¡
|
|
P. Sherrill Neff
|
o
|
|
WITHHOLD AUTHORITY
FOR ALL NOMINEES
|
|
|
|
|
|
|
|
|
|
|
|
o
|
|
FOR ALL EXCEPT (See instructions below)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INSTRUCTIONS:
|
|
To withhold authority to vote for any
individual nominee(s), mark FOR ALL EXCEPT and fill in
the circle next to each nominee you wish to withhold, as
shown here: l |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To change the address on your account, please check
the box at right and indicate your new address in
the address space above. Please note that changes
to the registered name(s) on the account may not be
submitted via this method. |
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
2. |
|
Proposal to approve the Amended
and Restated 2007 Equity Incentive Plan. |
|
|
o |
| |
o
|
|
|
o |
|
|
|
|
|
|
| |
|
|
|
|
3. |
|
Proposal to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for Amicus Therapeutics, Inc. for fiscal year ending December 31, 2008. |
|
|
o |
| |
o
|
|
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature of Stockholder |
|
|
|
Date: |
|
|
|
Signature of Stockholder |
|
|
|
Date: |
|
|
|
|
|
|
|
n |
|
Note: |
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person. |
n |
ANNUAL MEETING OF STOCKHOLDERS OF
Amicus Therapeutics, Inc
June 10, 2008
PROXY VOTING INSTRUCTIONS
MAIL -
Sign, date and mail your proxy card in the envelope provided as soon as possible.
-
OR -
TELEPHONE
- -
Call toll-free 1-800-PROXIES
(1-800-776-9437) in the United States or 1-718-
921-8500 from foreign countries and follow the
instructions. Have your proxy card available when
you call.
-
OR -
INTERNET
- -
Access www.voteproxy.com and follow the on-screen instructions. Have
your proxy card available when you access the web page.
-
OR -
IN
PERSON -
You may vote your shares in person by attending the Annual Meeting.
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPANY NUMBER |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACCOUNT NUMBER |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
You may enter your
voting instructions at 1-800-PROXIES in the United States or 1-718-921-8500 from foreign countries or www.voteproxy.com up until 11:59 PM
Eastern Time June 9, 2008.
ê Please detach along perforated line and mail
in the envelope provided IF you are not voting via telephone or the
Internet. ê
|
|
|
|
|
20330300000000000000 3 |
061008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THE BOARD OF
DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF
DIRECTORS AND FOR PROPOSALS 2 AND 3. PLEASE SIGN, DATE AND RETURN PROMPTLY
IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS
SHOWN HERE ý
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
1. Election of Directors: |
|
|
|
|
|
|
|
|
2. |
|
Proposal to approve the Amended and Restated 2007 Equity
Incentive Plan. |
|
o |
|
o |
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOMINEES: |
|
|
|
|
|
|
|
|
|
|
|
|
o |
|
FOR ALL NOMINEES |
|
¡ |
|
Alexander E. Barkas |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¡ |
|
Stephen Bloch |
|
|
|
|
3. |
|
Proposal to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for Amicus Therapeutics, Inc. for fiscal year ending December 31, 2008 |
|
o |
|
o |
|
o |
o |
|
WITHHOLD AUTHORITY |
|
¡ |
|
P. Sherrill Neff |
|
|
|
|
|
|
|
FOR ALL NOMINEES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o |
|
FOR ALL EXCEPT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(See instructions below) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INSTRUCTIONS:
To withhold authority to vote for any individual nominee(s), mark "FOR
ALL EXCEPT" and fill in the circle next to each nominee you wish to
withhold, as shown here: = |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To change the address on your account, please check
the box at right and indicate your new address in the address space above.
Please note that changes to the registered name(s) on the account may not
be submitted via this method. |
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature of
Stockholder |
|
Date: |
|
Signature of Stockholder |
|
Date: |
|
|
|
|
|
|
|
|
|
|
Note: |
|
Please sign exactly as your name or names
appear on this Proxy. When shares are held jointly, each holder
should sign. When signing as executor, administrator, attorney,
trustee or guardian, Please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person. |
|
|
AMICUS THERAPEUTICS, INC
6 Cedar Brook Drive
Cranbury, NJ 08512
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned stockholder of Amicus Therapeutics, Inc. hereby appoints Matthew R.
Patterson and James E. Dentzer as proxies, each with full power of substitution, to represent
and vote as designated on the reverse side, all the shares of Common Stock of Amicus
Therapeutics, Inc. held of record by the undersigned on April 21,2008, and which the
undersigned would be entitled to vote if personally present at the Annual Meeting of
Stockholders to be held at the Princeton Marriott Hotel & Conference Center at Forrestal, 100
College Road, Princeton, New Jersey, on June 10, 2008, or any adjournment or postponement
thereof.
This proxy is revocable and the undersigned may revoke it at any time prior to the Annual
Meeting by giving written notice of such revocation to the Secretary of Amicus Therapeutics,
Inc. prior to the meeting or by filing with the Secretary of Amicus Therapeutics, Inc. prior to
the meeting a later-dated proxy. Should the undersigned be present and want to vote in person
at the Annual Meeting, or at any postponement or adjournment thereof, the undersigned may
revoke this proxy by giving written notice of such revocation to the Secretary of Amicus
Therapeutics, Inc. on a form provided at the Annual Meeting. The undersigned hereby
acknowledges receipt of a notice of Anuual Meeting of Stockholders of Amicus Therapeutics, Inc.
called for June 10, 2008. and the Proxy Statement for the Annual Meeting, each dated April 25,
2008, prior to the signing of this proxy.
(Continued and to be signed on the reverse side)